Novo Integrated Sciences (NVOS) 10-K18 Dec 242024 FY Annual reportFinancial data

Company Profile

Cover

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Aug. 31, 2024	Dec. 17, 2024	Feb. 29, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Aug. 31, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--08-31
Entity File Number	001-40089
Entity Registrant Name	Novo Integrated Sciences, Inc.
Entity Central Index Key	0001138978
Entity Tax Identification Number	59-3691650
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	11120 NE 2nd Street
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	(206)
Local Phone Number	617-9797
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 10,240,619
Entity Common Stock, Shares Outstanding		19,730,247
Documents Incorporated by Reference [Text Block]	None
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Listing, Par Value Per Share	$ 0.001
Auditor Firm ID	5525
Auditor Name	Fruci & Associates II, PLLC
Auditor Location	Spokane, Washington

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Current Assets:
Cash and cash equivalents	$ 844,584	$ 416,323
Accounts receivable, net	1,916,819	1,467,028
Inventory, net	1,000,742	1,106,983
Other receivables	1,235,423	1,051,584
Prepaid expenses and other current assets	417,282	346,171
Total current assets	5,414,850	4,388,089
Property and equipment, net	5,110,776	5,390,038
Intangible assets, net	13,369,868	16,218,539
Right-of-use assets, net	1,691,309	1,983,898
Goodwill	6,554,473	7,582,483
TOTAL ASSETS	32,141,276	35,563,047
Current Liabilities:
Accounts payable	3,235,800	3,513,842
Accrued expenses	1,592,288	1,233,549
Accrued interest (including amounts to related parties)	624,287	382,666
Government loans and notes payable, current portion	45,681	277,405
Convertible notes payable, net of discount of $3,505,849	2,704,151	558,668
Derivative liability	4,685,198
Contingent liability	13,836	61,767
Finance lease liability, current portion	4,354	11,744
Operating lease liability, current portion	403,291	415,392
Total current liabilities	14,579,412	7,904,858
Government loans and notes payable, net of current portion	112,001	65,038
Operating lease liability, net of current portion	1,440,367	1,693,577
Deferred tax liability	1,395,571	1,400,499
TOTAL LIABILITIES	17,527,351	11,063,972
Commitments and contingencies
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; Nil shares issued and outstanding at August 31, 2024 and August 31, 2023
Common stock; $0.001 par value; 499,000,000 shares authorized; 19,054,523 and 15,759,325 shares issued and outstanding at August 31, 2024 and August 31, 2023, respectively	19,055	15,760
Additional paid-in capital	96,660,607	90,973,316
Common stock to be issued (1,700 and 91,138 shares at August 31, 2024 and August 31, 2023)	25,500	1,217,293
Other comprehensive (loss) income	1,387,244	(357,383)
Accumulated deficit	(83,199,785)	(67,033,041)
Total Novo Integrated Sciences, Inc. stockholders’ equity	14,892,621	24,815,945
Noncontrolling interest	(278,696)	(316,870)
Total stockholders’ equity	14,613,925	24,499,075
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	32,141,276	35,563,047
Related Party [Member]
Current Liabilities:
Debentures, related parties, current portion	913,598	916,824
Due to related parties	$ 356,928	$ 533,001

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Statement of Financial Position [Abstract]
Convertible notes payable net of discount current	$ 3,505,849	$ 3,505,849
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	499,000,000	499,000,000
Common stock, shares issued	19,054,523	15,759,325
Common stock, shares outstanding	19,054,523	15,759,325
Common stock to be issued, shares	1,700	91,138

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Aug. 31, 2024	Aug. 31, 2023
Income Statement [Abstract]
Revenues	$ 13,294,357	$ 12,572,019
Cost of revenues	7,551,853	7,619,304
Gross profit	5,742,504	4,952,715
Operating expenses:
Selling expenses	17,137	15,149
General and administrative expenses	14,039,265	13,490,728
Impairment of assets	761,067
Goodwill impairment	1,001,333
Total operating expenses	15,818,802	13,505,877
Loss from operations	(10,076,298)	(8,553,162)
Non-operating income (expense)
Interest income	202,525	9,027
Interest expense	(652,398)	(360,571)
Other (expense) income	(1,032,620)	607,589
Change in fair value of derivative liability	3,594,171
Amortization of debt discount	(6,574,862)	(4,757,121)
Foreign currency transaction losses	(1,589,088)	(215,206)
Total other income (expense)	(6,052,272)	(4,716,282)
Loss before income taxes	(16,128,570)	(13,269,444)
Income tax expense (recovery)
Net loss	(16,128,570)	(13,269,444)
Net loss attributed to noncontrolling interest	38,174	(54,892)
Net loss attributed to Novo Integrated Sciences, Inc.	(16,166,744)	(13,214,552)
Comprehensive loss:
Net loss	(16,128,570)	(13,269,444)
Foreign currency translation loss	(1,744,627)	(922,609)
Comprehensive loss:	$ (17,873,197)	$ (14,192,053)
Weighted average common shares outstanding - basic	18,032,015	10,165,548
Weighted average common shares outstanding - diluted	18,032,015	10,165,548
Net loss per common share - basic	$ (0.89)	$ (1.30)
Net loss per common share - diluted	$ (0.89)	$ (1.30)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock To Be Issued [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Aug. 31, 2022	$ 3,118	$ 66,084,887	$ 9,474,807	$ 560,836	$ (53,818,489)	$ 22,305,159	$ (257,588)	$ 22,047,571
Balance, shares at Aug. 31, 2022	3,118,063
Units issued for cash, net of offering costs	$ 400	1,794,600				1,795,000		$ 1,795,000
Units issued for cash, net of offering costs, shares	400,000							400,000
Cashless exercise of warrants	$ 583	1,421,000				1,421,583		$ 1,421,583
Cashless exercise of warrants, shares	583,334
Shares issued for convertible debt settlement	$ 10,178	9,957,962				9,968,140		9,968,140
Shares issued for convertible debt settlement, shares	10,177,834
Exercise of warrants for cash	$ 533	532,067				532,600		532,600
Exercise of warrants for cash, shares	532,600
Shares issued with convertible notes	$ 265	247,622				247,887		247,887
Shares issued with convertible notes, shares	265,167
Value of warrants issued with convertible notes		257,994				257,994		257,994
Beneficial conversion feature upon issuance on convertible debt		164,046				164,046		164,046
Extinguishment of derivative liability due to conversion		1,390,380				1,390,380		1,390,380
Common stock issued for services	$ 359	480,233				480,592		480,592
Common stock issued for services, shares	358,500
Issuance of common stock to be issued	$ 324	8,257,190	(8,257,514)
Issuance of common stock to be issued, shares	323,827
Fair value of stock options		385,335				385,335		385,335
Foreign currency translation loss				(918,219)		(918,219)	(4,390)	(922,609)
Net loss					(13,214,552)	(13,214,552)	(54,892)	(13,269,444)
Balance at Aug. 31, 2023	$ 15,760	90,973,316	1,217,293	(357,383)	(67,033,041)	24,815,945	(316,870)	24,499,075
Balance, shares at Aug. 31, 2023	15,759,325
Cashless exercise of warrants	$ 246	1,323,152				1,323,398		1,323,398
Cashless exercise of warrants, shares	245,802
Shares issued for convertible debt settlement	$ 2,283	1,608,600				1,610,883		1,610,883
Shares issued for convertible debt settlement, shares	2,283,176
Exercise of warrants for cash	$ 240	240,160				240,400		240,400
Exercise of warrants for cash, shares	240,400
Common stock issued for services	$ 424	1,194,976				1,195,400		1,195,400
Common stock issued for services, shares	424,080
Issuance of common stock to be issued	$ 74	1,172,776	(1,172,850)
Issuance of common stock to be issued, shares	73,767
Fair value of stock options		147,655				147,655		147,655
Foreign currency translation loss				1,744,627		1,744,627		1,744,627
Net loss					(16,166,744)	(16,166,744)	38,174	(16,128,570)
Reverse stock split share rounding	$ 28	(28)
Reverse stock split share rounding, shares	27,973
Cancellation of agreement			(18,943)			(18,943)		(18,943)
Balance at Aug. 31, 2024	$ 19,055	$ 96,660,607	$ 25,500	$ 1,387,244	$ (83,199,785)	$ 14,892,621	$ (278,696)	$ 14,613,925
Balance, shares at Aug. 31, 2024	19,054,523

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Aug. 31, 2024	Aug. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (16,128,570)	$ (13,269,444)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,261,519	2,302,754
Fair value of vested stock options	147,656	385,335
Financing costs for debt extension		1,421,583
Change in fair value of derivative liability	(3,594,171)
Default payment and interest paid through common share issuance		205,349
Cashless exercise of warrants	1,323,398
Common stock issued for services	1,195,400	480,592
Operating lease expense	616,799	797,515
Cancellation of shares to be issued	62,130
Amortization of debt discount	6,574,862	4,757,121
Foreign currency transaction losses	1,589,088	215,206
Impairment of assets	761,067
Assets write off	321,872
Goodwill impairment	1,001,333
Changes in operating assets and liabilities:
Accounts receivable	(453,252)	(597,191)
Inventory	(210,883)	(255,781)
Prepaid expenses and other current assets	(259,972)	210,382
Accounts payable	(267,211)	1,770,589
Accrued expenses	330,276	153,598
Accrued interest	275,618	(58,066)
Operating lease liability	(616,799)	(762,852)
Net cash used in operating activities	(5,069,840)	(2,243,315)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(5,034)	(49,224)
Net cash (used in) provided by investing activities	(5,034)	(49,224)
CASH FLOWS FROM FINANCING ACTIVITIES:
(Repayments to) receipt from related parties	(396,418)	7,206
Proceeds from notes payable	402	222,780
Repayments of notes payable	(183,725)	(37,130)
Repayments of finance leases	(7,334)	(8,611)
Proceeds from issuance of convertible notes	8,649,153	1,285,903
Repayment of convertible notes	(3,311,536)	(3,033,888)
Proceeds from the sale of common stock, net of offering costs		1,795,000
Proceeds from exercise of warrants	240,400	532,600
Net cash provided by financing activities	4,990,942	763,860
Effect of exchange rate changes on cash and cash equivalents	512,193	(233,685)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	428,261	(1,762,364)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	416,323	2,178,687
CASH AND CASH EQUIVALENTS, END OF YEAR	844,584	416,323
CASH PAID FOR:
Interest	190,491	432,094
Income taxes
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for convertible debt	$ 1,610,883	$ 9,968,140
Common stock issued for acquisition
Warrants issued with convertible notes		257,994
Beneficial conversion feature upon issuance of convertible notes		$ 164,046
Debt discount recognized on derivative liability		1,390,380
Extinguishment of derivative liability due to conversion		1,390,380
Debt discount recognized on convertible note		975,024
Common stock issued with convertible notes		247,887
Common stock issued for services	1,195,400
Cashless exercise of warrants	$ 1,323,398

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
Pay vs Performance Disclosure - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (16,166,744)	$ (13,214,552)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Aug. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
Organization and Basis of Presentation	Aug. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation Organization and Line of Business Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries. The Company owns Canadian and U.S. subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutics, diagnostic solutions, unique personalized product offerings, and rehabilitative science. We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered now and how it will be delivered in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective and efficient healthcare distribution. The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers: ● First Pillar – Service Networks: Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities. ● Second Pillar – Technology: Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home. ● Third Pillar – Products: Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions. On April 25, 2017 (the “Effective Date”), we entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) Novo Integrated; (ii) Novo Healthnet Limited (“NHL”), (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, Novo Integrated agreed to acquire, from the NHL Shareholders, all of the shares of both common and preferred stock of NHL held by the NHL Shareholders in exchange for the issuance, by Novo Integrated to the NHL Shareholders, of shares of Novo Integrated common stock such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 1,677,974 85 On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated. The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Share Exchange Agreement was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, novo Integrated Sciences, Inc., were $ 6,904 Reverse Stock Split On November 7, 2023, the Company effected a 1-for-10 reverse stock split 1-for-10 reverse stock split Basis of Presentation The accompanying consolidated financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD”) and the Parent company’s functional currency is the United States Dollar (“$” or “USD”); however, the accompanying consolidated financial statements were translated and presented in USD. Going Concern The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date the consolidated financial statements are issued. The Company has incurred recurring losses from operations, has negative cash flows from operating activities, and has an accumulated deficit as at of August 31, 2024. The Company believes that its cash and other available resources may not be sufficient to meet its operating needs and the payment of obligations related to various business acquisitions as they come due within one year after the date the consolidated financial statements are issued. To alleviate these conditions, the Company is currently in the process of raising funds through debt financing and a subsequent public offering in the United States. As the Company’s funding activities are ongoing, there can be no assurances that the Company will be able to secure funding on terms that are acceptable to the Company. These conditions, along with the matters noted above, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. While management has developed and is in process to implement plans that management believes could alleviate in the future the substantial doubt that was raised, management concluded at the date of the issuance of the consolidated financial statements that substantial doubt exists as those plans are not completely within the control of management. These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and consolidated balance sheets classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material. Foreign Currency Translation The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction Comprehensive Income Schedule of Foreign Currency Translation, Exchange Rate Used August 31, 2024 August 31, 2023 Period end: CAD to USD exchange rate $ 0.7364 $ 0.7390 Average period: CAD to USD exchange rate $ 0.7349 $ 0.7426

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Aug. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to the going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91 50.1 80 70 All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation. Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and comprehensive loss. Cash Equivalents For the purpose of the consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less. Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of August 31, 2024 and 2023, the allowance for uncollectible accounts receivable was $ 1,273,596 864,215 10 nil Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of August 31, 2024 and 2023, the Company’s allowance for slow moving or obsolete inventory was $ nil nil Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the years ended August 31, 2024 and 2023, the Company wrote off $ nil nil Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful Lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5 Leases The Company applies the provisions of ASC Topic 842, Leases Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at August 31, 2024 and 2023, the Company believes there was $ 1,726,776 nil impairment of assets Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. As of August 31, 2024, the Company performed the required impairment reviews and determined that an impairment charge of $ 742,120 259,213 Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2022 190,678 125,088 221,188 7,288,307 583 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 184,750 121,196 214,310 7,061,662 565 7,582,483 Beginning balance 184,750 121,196 214,310 7,061,662 565 7,582,483 Impairment of goodwill (92,375 ) (60,598 ) (106,240 ) (742,120 ) - (1,001,333 ) Foreign currency translation adjustment (2,461 ) (1,614 ) (2,830 ) (19,770 ) (2 ) (26,677 ) Balance, August 31, 2024 89,914 58,984 105,240 6,299,772 563 6,554,473 Ending balance 89,914 58,984 105,240 6,299,772 563 6,554,473 Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, and current liabilities, including accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of August 31, 2024 and 2023, respectively, the Company did not identify any financial assets and liabilities required to be presented on the consolidated balance sheet at fair value, except for contingent liability which is carried at fair value using Level 1 inputs and derivative liability which is carried at fair value using Level 3 inputs. Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives. Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of ASU No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying consolidated balance sheets. Sales returns and allowances were insignificant for the years ended August 31, 2024 and 2023. The Company does not provide unconditional right of return, price protection or any other concessions to its customers. Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented. Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 826,616 1,777,678 24,608,975 1,700 Due to the net loss incurred potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented. Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gain of $ 1,744,627 922,609 Consolidated Statements of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Segment Reporting ASC Topic 280, Segment Reporting Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. In December 2021, the FASB issued an update to ASU No. 2016-13 the Current Expected Credit Losses (CECL) standard (ASC 326), which is designed to provide greater transparency and understanding of credit risk by incorporating estimated, forward-looking data when measuring lifetime Estimated Credit Losses (ECL) and requires enhanced financial statement disclosures. This guidance was adopted during the year ended August 31, 2024, and as a result an increase in the allowance is recorded. In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures In March 2020, the FASB issued ASU No. 2020-04 providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020, could be applied through December 31, 2022. In December 2022, the FASB issued No 2022-06 extending the sunset date of the relief provided under ASU No. 2020-04 to December 31, 2024. The ASU has not impacted these consolidated financial statements. The Company has various contracts that reference LIBOR and is assessing how this standard may be applied to specific contract modifications through December 31, 2024. Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Aug. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 3 – Related Party Transactions Due to related parties Amounts loaned to the Company by stockholders and officers of the Company are payable upon demand and unsecured. At August 31, 2024 and 2023, the amount due to related parties was $ 356,928 533,001 275,351 nil 6 81,577 13.75 451,137 21,267 6 60,597 13.75 The remaining principal balance of debentures due to related parties at August 31, 2024 and 2023 was $ 913,598 916,824

Inventory

Inventory	12 Months Ended
Inventory	Aug. 31, 2024
Inventory Disclosure [Abstract]
Inventory	Note 4 – Inventory Inventory at August 31, 2024 and 2023 consisted of the following: Schedule of Inventory 2024 2023 Raw materials $ 227,471 $ 388,391 Work in process 225,089 81,696 Finished Goods 548,182 636,896 Inventory Gross 1,000,742 1,106,983 Allowance for slow moving and obsolete inventory - - Inventory, net $ 1,000,742 $ 1,106,983

Accounts Receivables, net

Accounts Receivables, net	12 Months Ended
Accounts Receivables, net	Aug. 31, 2024
Receivables [Abstract]
Accounts Receivables, net	Note 5 – Accounts Receivables, net Accounts receivables, net at August 31, 2024 and 2023 consisted of the following: Schedule of Accounts Receivable, Net 2024 2023 Trade receivables $ 3,173,068 $ 2,223,243 Amounts earned but not billed 17,347 108,000 Accounts receivables gross 3,190,415 2,331,243 Allowance for doubtful accounts (1,273,596 ) (864,215 ) Accounts receivable, net $ 1,916,819 $ 1,467,028

Other Receivables

Other Receivables	12 Months Ended
Other Receivables	Aug. 31, 2024
Receivables [Abstract]
Other Receivables	Note 6 – Other Receivables Other receivables at August 31, 2024 and 2023 consisted of the following: Schedule of Other Receivables 2024 2023 Advance to corporation; accrues interest at 12 December 31, 2024 73,640 73,900 Advance to corporation; accrues interest at 12 December 31, 2024 646,302 534,386 Advance to corporation; accrues interest at 10 December 31, 2024 515,481 443,298 Total other receivables 1,235,423 1,051,584 Current portion (1,235,423 ) (1,051,584 ) Long-term portion $ - $ -

Property and Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Aug. 31, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 7 – Property and Equipment Property and equipment at August 31, 2024 and 2023 consisted of the following: Schedule of Property and Equipment 2024 2023 Land $ 441,840 $ 443,400 Building 3,313,800 3,325,500 Leasehold improvements 764,091 841,371 Clinical equipment 1,908,833 1,916,681 Computer equipment 38,430 33,504 Office equipment 44,404 44,502 Furniture and fixtures 38,154 38,289 Property and Equipment gross 6,549,552 6,643,247 Accumulated depreciation (1,438,776 ) (1,253,209 ) Total $ 5,110,776 $ 5,390,038 Depreciation expense for the years ended August 31, 2024 and 2023 was $ 259,510 292,041 Certain property and equipment have been used to secure notes payable (See Note 10).

Intangible Assets

Intangible Assets	12 Months Ended
Intangible Assets	Aug. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 8 – Intangible Assets Intangible assets at August 31, 2024 and 2023 consisted of the following: Schedule of Intangible Assets 2024 2023 Land use rights $ 10,968,933 $ 11,573,321 Intellectual property 7,331,114 7,497,746 Customer relationships 2,145,917 2,291,058 Brand names 1,921,636 1,928,421 Finite lived intangible assets, gross 22,367,600 23,290,546 Accumulated amortization (8,997,732 ) (7,072,007 ) Total $ 13,369,868 $ 16,218,539 Amortization expense for the years ended August 31, 2024 and 2023 was $ 2,002,009 2,010,713 Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of intangible Assets Years Ending August 31, 2025 $ 2,125,036 2026 1,310,941 2027 1,094,292 2028 759,115 2029 219,379 Thereafter 7,861,105 Total $ 13,369,868 On January 7, 2019, 2478659 Ontario Ltd. (“247”) and Kainai Cooperative (“Kainai”) entered into a Joint Venture Agreement (the “Joint Venture Agreement”) for the purpose of developing, managing and arranging for financing of greenhouse and farming projects involving hemp and cannabis cash crops on Kainai related lands, and developing additional infrastructure projects creating jobs and food supply to local communities. On January 8, 2019, we and 247 entered into an Agreement of Transfer and Assignment, pursuant to which 247 agreed to sell, assign and transfer to the Company all rights, contracts, contacts and any and all other assets related in any way to the Joint Venture Agreement. Pursuant to the terms of the Joint Venture Agreement, as assigned to us, the parties will work in a joint venture relationship (“JV”) with the Company providing the finance, development and operation of the project, including sales, and Kainai providing the land and approvals for the development of the projects. Pursuant to the terms of the Joint Venture Agreement, (i) the Company has an 80% controlling interest and Kainai has a 20% interest in the JV; and (ii) the Company has sole discretion to identify the name and entity under which the JV will operate. The legal entity in which the JV will operate has not yet been identified or formed. The JV operations will primarily involve the production – including processing, packaging and sales of natural supplements derived from hemp derived cannabis oils. The joint venture will distribute to the Company and Kainai all net proceeds after debt and principal servicing and repayment allocation, as well as operating capital allotment, on a ratio equal to 80% to the Company and 20% to Kainai. 50 120,000 21,600,000 604,388 10,026,679 On December 17, 2019, the Company entered into that certain Intellectual Property Asset Purchase Agreement (the “APA”) by and between the Company and 2731861 Ontario Corp. (the “Seller”), pursuant to which the Company agreed to purchase, and Seller agreed to sell (the “Acquisition”), proprietary designs for an innovative cannabis dosing device, in addition to designs, plans, procedures, and all other material pertaining to the application, construction, operation, and marketing of a cannabis business under the regulations of Health Canada (the “Intellectual Property”). Pursuant to the terms of the APA, the purchase price of the Intellectual Property is 80,000 5,248,000 53,206 1,858,179 In connection with the acquisition of PRO-DIP (see Note 16), the Company acquired intellectual property valued at $ 455,752 103,476 52,752 In connection with the acquisition of Acenzia (See Note 16), the Company acquired the following intangible assets: intellectual property valued at $ 2,875,000 806,000 2,115,000 In connection with the acquisition of Terragenx (see Note 16), the Company acquired intellectual property valued at $ 1,179,361 In connection with the acquisition of 1285 Canada (see Note 16), the Company acquired customer relationships valued at $ 31,101 In connection with the acquisition of Poling Taddeo Hovius Physiotherapy Professional Corp. (see Note 16), the Company acquired customer relationships valued at $ 151,686 In connection with the acquisition of Clinical Consultants International LLC (see Note 16), the Company acquired customer relationships valued at $ 1,701,814 nil 317,314)

Accrued Expenses

Accrued Expenses	12 Months Ended
Accrued Expenses	Aug. 31, 2024
Payables and Accruals [Abstract]
Accrued Expenses	Note 9 – Accrued Expenses Accrued expenses at August 31, 2024 and 2023 consisted of the following: Schedule of Accrued Expenses 2023 2023 Accrued liabilities $ 1,084,148 $ 961,897 Accrued payroll 268,772 236,218 Unearned revenue 239,368 35,434 Accrued expense $ 1,592,288 $ 1,233,549

Government Loans and Note Payab

Government Loans and Note Payable and Government Subsidy	12 Months Ended
Government Loans and Note Payable and Government Subsidy	Aug. 31, 2024
Government Loans And Note Payable And Government Subsidy
Government Loans and Note Payable and Government Subsidy	Note 10 – Government Loans and Note Payable and Government Subsidy Governmental loans and note payable at August 31, 2024 and 2023 consisted of the following: Schedule of Governmental Loans and Note Payable 2024 2023 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A) 88,770 88,680 Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75 190 40,320 40,320 Note payable dated December 3, 2018; accrues interest at 4.53 4,000 28,592 28,693 Note payable received May 25, 2023 accruing interest at 18 - 73,900 Note payable received May 10, 2023 accruing interest at 15 - 110,850 Total government loans and notes payable 157,682 342,443 Less current portion (45,681 ) (277,405 ) Long-term portion $ 112,001 $ 65,038 (A) The Government of Canada launched the Canada Emergency Business Account (“CEBA”) loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained a CAD$ 80,000 59,120 January 18, 2024 25 75 5 60,000 20,000 29,332 Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of Government Loans and Notes Payable Years Ending August 31, 2025 $ 45,681 2026 45,681 2027 21,925 2028 8,172 2029 3,646 Thereafter 32,577 Total $ 157,682

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
Convertible Notes Payable	Aug. 31, 2024
Convertible Notes Payable
Convertible Notes Payable	Note 11 – Convertible Notes Payable Novo Integrated On December 14, 2021, Novo Integrated issued two convertible notes payable for a total of $ 16,666,666 8,333,333 5 June 14, 2023 20 In connection with the $16.66m+ convertible notes, the Company issued the note holders warrants to purchase a total of 583,334 20 December 14, 2025 7,680,156 ● Expected life of 4.0 ● Volatility of 275 ● Dividend yield of 0 ● Risk free interest rate of 1.23 The face amount of the $16.66m+ convertible notes of $ 16,666,666 11,409,200 5,257,466 5,257,466 1,666,666 1,140,000 8,064,132 16.66 Terragenx On November 17, 2021, Terragenx, a 91 1,875,000 937,500 1 May 17, 2022 33.50 In connection with the $1.875m convertible notes, the Company issued the note holders warrants to purchase a total of 22,388 33.50 November 17, 2024 351,240 ● Expected life of 3.0 ● Volatility of 300 ● Dividend yield of 0 ● Risk free interest rate of 0.85 The face amount of the $1.875m convertible notes of $ 1,875,000 1,579,176 295,824 295,824 375,000 90,000 760,824 760,824 0 On June 1, 2022, the Company paid the balance owed on one of two Terragenx $ 1.875 948,874 1.875 192,188 November 29, 2022 937,500 On June 1, 2022, the Company and one of the two Terragenx $ 1.875 November 29, 2022 186,719 Effective February 16, 2023, aside from the Liquidated Damages Charge, the Jefferson Note was paid in full. On August 21, 2023, Jefferson converted the additional Liquidated Damages Charge and the interest thereon. On August 21, 2023, as a result of the conversion, the Company issued 236,511 nil Novo Integrated – Mast Hill Fund, L.P. $573,000 Note, SPA, and Warrant On February 23, 2023, the Company entered into a securities purchase agreement (the “Mast Hill SPA”) with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued an 12 February 23, 2024 573,000 100,000 12 57,300 515,700 1.75 Pursuant to the terms of the Mast Hill Note, the Company agreed to pay accrued interest monthly as well as the Mast Hill Principal Sum as follows: (i) $ 57,300 57,300 57,300 100,000 100,000 100,000 85 The Company may prepay the Mast Hill Note at any time prior to the date that an Event of Default (as defined in the Mast Hill Note) occurs at an amount equal to the Mast Hill Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any Event of Default, the Mast Hill Note shall become immediately due and payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the Mast Hill Principal Sum then outstanding plus accrued interest multiplied by 125 16 The Mast Hill Warrant is exercisable for five years from February 23, 2023, at an exercise price of $ 2.50 86,327 ● Expected life of 5.0 ● Volatility of 252 ● Dividend yield of 0 ● Risk free interest rate of 4.09 As additional consideration for the purchase of the Mast Hill Note and pursuant to the terms of the Mast Hill SPA, on February 24, 2023, the Company issued 95,500 19.99 2,772,045 The principal amount of the $ 573,000 403,710 82,963 86,327 57,300 70,465 297,055 nil 297,055 nil During the year ended August 31, 2023, the principal amount of $ 573,000 6,028 1,750 522,777 nil On August 24, 2023, the total principal and interest of $ 580,778 573,000 522,777 1.11095 573,000 On September 18, 2023, Mast Hill fully exercised all warrants issued pursuant to the terms and conditions of the $ 573,000 53,567 573,000 Novo Integrated – FirstFire Global Opportunities Fund, LLC $573,000 Note, SPA, and Warrant On March 21, 2023, the Company entered into a securities purchase agreement (the “SPA”) with FirstFire Global Opportunities Fund, LLC (“FirstFire”) pursuant to which the Company issued an 12 March 21, 2024 573,000 100,000 12 57,300 515,700 1.75 Pursuant to the terms of the 2023 FirstFire Note, the Company agreed to pay accrued interest monthly as well as the Principal Sum as follows: (i) $ 57,300 57,300 57,300 100,000 100,000 100,000 85 The Company may prepay the 2023 FirstFire Note at any time prior to the date that an event of default (as provided in the 2023 FirstFire Note) occurs at an amount equal to the Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any event of default, the 2023 FirstFire Note shall become immediately due and payable and the Company shall pay to FirstFire, in full satisfaction of its obligations hereunder, an amount equal to the Principal Sum then outstanding plus accrued interest multiplied by 125 16 The 2023 FirstFire Warrant is exercisable for five years from March 21, 2023, at an exercise price of $ 2.50 93,811 ● Expected life of 5.0 ● Volatility of 251 ● Dividend yield of 0 ● Risk free interest rate of 3.73 As additional consideration for the purchase of the 2023 FirstFire Note and pursuant to the terms of the SPA, on March 22, 2023, the Company issued 95,500 1,000,000 The principal amount of the $ 573,000 389,057 90,132 93,811 57,300 35,628 The effective conversion price was determined to be $ 1.188 1.390 66,068 The combined total discount is $ 342,938 152,729 190,209 Novo Integrated – Mast Hill Fund, L.P.$445,000 Note, SPA, and Warrant On June 20, 2023, the Company entered into a securities purchase agreement (the “MH $445,000 SPA”) with Mast Hill, pursuant to which the Company issued an 12 June 20, 2024 445,000 77,662 12 44,500 400,500 1.75 Pursuant to the terms of the MH $445,000 Note, the Company agreed to pay accrued interest monthly as well as the MH $445,000 Principal Sum as follows: (i) $ 44,500 44,500 44,500 77,661 77,661 77,661 85 The Company may prepay the MH $445,000 Note at any time prior to the date that an Event of Default (as defined in the Note) (each an “MH $445,000 Event of Default”) occurs at an amount equal to the MH $445,000 Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any MH $445,000 Event of Default, the MH $445,000 Note shall become immediately due and payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the MH $445,000 Principal Sum then outstanding plus accrued interest multiplied by 125 The MH $445,000 Warrant is exercisable for five years from June 20, 2023, at an exercise price of $ 2.50 77,856 ● Expected life of 5.0 ● Volatility of 251 ● Dividend yield of 0 ● Risk free interest rate of 3.96 As additional consideration for the purchase of the MH $445,000 Note and pursuant to the terms of the MH $445,000 SPA, the Company issued 74,167 1,772,045 The principal amount of the $445,000 convertible notes was proportionately allocated to the convertible note, common stock issued, and the warrants in the amount of $ 292,351 74,793 77,856 44,500 39,904 The effective conversion price was determined to be $ 1.150 1.535 97,978 The combined total discount is $ 335,031 65,908 269,123 Specific to the MH $445,000 Note, on July 20, 2023, the Company made a monthly interest payment of $ 4,243 4,535 4,535 4,389 On October 23, 2023, Mast Hill fully exercised all warrants issued pursuant to the terms and conditions of the MH $445,000 Mast Hill Warrant Agreement, dated June 20, 2023. Under certain cashless exercise provisions, as well as price protection provisions providing for adjustment of the number of shares of the Company’s common stock issuable upon exercise of the Mast Hill Warrant, the Company issued 138,703 On December 21, 2023, the total principal and interest of $ 454,071 457,128 1.11095 Novo Integrated - Streeterville Capital, LLC April 2024 Note and SPA On April 5, 2024, the Company entered into a securities purchase agreement (the “Streeterville SPA”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which the Company issued a secured convertible promissory note (the “Streeterville Note”) with a maturity date of April 8, 2025 6,210,000 10.9 660,000 50,000 5,500,000 3,500,000 277,777.77 Streeterville may convert the Streeterville Note into the Company’s common stock on any trading day (and the following trading day) that any intraday trade price of the common stock is 10% greater than the closing trade price on the previous trading day (each a “Voluntary Conversion”). With respect to any Voluntary Conversion, the conversion price is equal to 85 Beginning on October 8, 2024, Streeterville shall have the right to redeem up to $ 950,000 The Company may prepay the Note at any time prior to the date that an Event of Default (as defined in the Streeterville Note) (each an “Event of Default”) occurs at an amount equal to 105% of the Outstanding Balance (as defined below). “Outstanding Balance” means the Streeterville Principal Sum then outstanding plus accrued and unpaid interest Upon the occurrence of any Event of Default, the Streeterville Note shall become immediately due and payable and the Company shall pay to Streeterville, in full satisfaction of its obligations hereunder, an amount equal to the Outstanding Balance plus the Trigger Effect (as defined herein). The “Trigger Effect” means 20% of the Outstanding Balance upon the occurrence of any Major Trigger Event (as defined in the Streeterville Note) and 5% of the Outstanding Balance upon the occurrence of any Minor Trigger Event (as defined in the Streeterville Note). The Trigger Effect for any Minor Trigger Event may occur up to three times. Upon the occurrence of an Event of Default, additional interest will accrue from the date of the Event of Default at the rate equal to the lower of 22% per annum or the highest rate permitted by law. In addition to the beneficial ownership limitations provided in the Streeterville Note, the sum of the number of shares of common stock that may be issued under the Streeterville SPA and Streeterville Note shall be limited to 19.99 The Streeterville SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, registration rights with respect to the common stock underlying the Streeterville Note. The Streeterville SPA also requires the Company to file a registration statement covering Streeterville’s resale of the common stock underlying the Streeterville Note within 75 days of the closing date. In connection with the Streeterville Note and Streeterville SPA, the Company and Streeterville also entered into a security agreement (the “Streeterville Security Agreement”). Pursuant to the Streeterville Security Agreement, the Company granted Streeterville a security interest in all of the assets of the Company. Acenzia, a wholly owned subsidiary of the Company, entered into a guaranty with Streeterville on April 5, 2024 (the “Acenzia Guaranty”). Acenzia guaranteed the repayment of the Streeterville Note and granted Streeterville a security interest in the assets of Acenzia, including but not limited to the property located at 1580 Rossi Drive, Tecumseh, Ontario, Canada. Further, NHL, a wholly owned subsidiary of the Company, entered into a guaranty with Streeterville on April 5, 2024 (the “NHL Guaranty”). NHL guaranteed the repayment of the Streeterville Note and granted a security interest in the assets of NHL. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. On April 5, 2024, the Company recorded a derivative liability of $ 5,010,966 ● Expected life of 1 ● Volatility of 186 ● Dividend yield of 0 ● Risk free interest rate of 5.05 The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible note. As of August 31, 2024, the fair value of the derivative liability was $ 4,685,198 322,383 ● Expected life of 0.60 ● Volatility of 200 ● Dividend yield of 0 ● Risk free interest rate of 4.38 The Streeterville Note contained a discount on note of $ 235,414 During the year ended August 31, 2024, the Company amortized $ 2,380,117 3,505,848

Debentures, related parties

Debentures, related parties	12 Months Ended
Debentures, related parties	Aug. 31, 2024
Debt Disclosure [Abstract]
Debentures, related parties	Note 12 – Debentures, related parties On September 30, 2013, the Company issued five debentures totaling CAD$ 6,402,512 6,225,163 8 September 30, 2016 September 30, 2019 December 1, 2023 On January 31, 2018, the debenture holders converted 75 3,894,809 414,965 1,047,588 4.11 the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $ 267,768 At August 31, 2024 and 2023, the amount of debentures outstanding was $ 913,598 916,824

Leases

Leases	12 Months Ended
Leases	Aug. 31, 2024
Leases
Leases	Note 13 – Leases Operating leases The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate. The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2031. The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of August 31, 2024 and 2023: Schedule of Lease Related Assets and Liabilities 2024 2023 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 1,691,309 $ 1,983,898 Total lease assets $ 1,691,309 $ 1,983,898 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 403,291 $ 415,392 Noncurrent liabilities Operating lease liability Long-term operating lease liability 1,440,367 1,693,577 Total lease liability $ 1,843,658 $ 2,108,969 Lease obligations at August 31, 2024 consisted of the following: Schedule of Lease Obligations Years Ending August 31, 2025 $ 547,571 2026 547,393 2027 510,676 2028 293,723 2029 173,588 Thereafter 167,269 Total payments 2,240,220 Amount representing interest (396,562 ) Lease obligation, net 1,843,658 Less lease obligation, current portion (403,291 ) Lease obligation, long-term portion $ 1,440,367 During the year ended August 31, 2024, the Company entered into new lease obligations of $ 157,973 The lease expense for the years ended August 31, 2024 and 2023 was $ 616,799 797,515 589,138 772,655 At August 31, 2024, the weighted average remaining lease terms were 3.75 8.7 Finance leases The Company leases certain equipment under lease contracts that are accounted for as finance leases. If the contracts meet the criteria for a finance lease, the related equipment underlying the lease contract is capitalized and amortized over its estimated useful life. If the cost of the equipment is not available, the Company calculates the cost by taking the present value of the lease payments using an implicit borrowing rate of 5 The net book value of equipment under finance leases included in property and equipment on the accompanying balance sheet at August 31, 2024 is as follows: Schedule of Finance Leases Cost $ 209,457 Accumulated amortization (209,457 ) Net book value $ - Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Years Ending August 31, 2025 $ 4,420 Total payments 4,420 Amount representing interest (66 ) Lease obligation, net 4,354 Less lease obligation, current portion (4,354 ) Lease obligation, long-term portion $ -

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
Stockholders’ Equity	Aug. 31, 2024
Equity [Abstract]
Stockholders’ Equity	Note 14 – Stockholders’ Equity Convertible preferred stock The Company has authorized 1,000,000 0.001 0 0 Common Stock The Company has authorized 499,000,000 0.001 On November 7, 2023, the Company effected a 1-for-10 reverse stock split 1-for-10 reverse stock split As of August 31, 2024 and 2023 there were 19,054,523 15,759,325 During the fiscal year ended August 31, 2024, the Company issued common stock, as follows: ● 80,200 3 80,200 ● 160,200 5 160,200 ● 75,000 September 5, 2023 ● 53,567 573,000 September 18, 2023 ● 75,000 September 18, 2023 ● 519,845 573,000 4,521 577,521 September 21, 2023 ● 75,000 October 3, 2023 ● 73,767 October 9, 2023 ● 53,532 573,000 October 12, 2023 ● 75,000 October 18, 2023 ● 138,703 445,000 October 23, 2023 ● 75,000 November 8, 2023 ● 30,675 November 21, 2023 ● 18,405 November 21, 2023 ● 27,973 1-for-10 reverse stock split ● 457,128 445,000 9,071 454,071 December 21, 2023 ● 826,203 271,226 104,712 375,938 between March 14, 2024 and April 4, 2024 ● 480,000 195,016 8,333 203,350 April 4, 2024 During the fiscal year ended August 31, 2023, the Company issued common stock, as follows: ● 400,000 5 The Company sold an aggregate of 400,000 2,000,000 400,000 400,000 three 400,000 5 400,000 five 400,000 5 140,000 7.0 1,795,000 The total fair value of the 800,000 1,137,959 149.06 206.90 0 2.55 2.89 2.956 3 5 ● 3,623 October 26, 2022 ● 291,667 November 15, 2022 ● 175,732 November 15, 2022 ● 3,916,596 3,825,307 February 28, 2023 ● 4,503,644 4,503,640 February 28, 2023 ● 890,711 757,103 February 28, 2023 ● 65,000 3 65,000 ● 115,935 ● 33,000 5 33,000 ● 33,000 3 33,000 ● 320,204 January 25, 2023 ● 95,500 February 24, 2023 ● 107,595 100,278 53,783 53,812 ● 160,000 3 160,000 ● 100,000 5 100,000 ● 95,500 March 22, 2023 ● 30,000 5 30,000 ● 30,000 3 30,000 ● 75,000 ● 74,167 ● 100,000 ● 33,500 ● 75,000 ● 75,000 ● 20,800 3 20,800 ● 20,800 5 20,800 ● 10,000 3 10,000 ● 30,000 5 30,000 ● 236,511 201,034 186,719 14,315 ● 522,777 580,778 Common Stock to be Issued As of August 31, 2024, in connection with the acquisition of 1285 Canada, the Company has allotted and is obligated to issue 1,700 25,500 Stock Options and Warrants On September 8, 2015, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2015 Incentive Compensation Plan (the “2015 Plan”), which authorizes the issuance of up to 50,000 49,875 On January 16, 2018, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2018 Incentive Compensation Plan (the “2018 Plan”). Under the 2018 Plan, 100,000 86,490 On February 9, 2021, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2021 Equity Incentive Plan (the “2021 Plan”). Under the 2021 Plan, a total of 450,000 the maximum aggregate number of shares that may be issued under the 2021 Plan may be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2023, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan effective January 1, 2022 and January 1, 2023. As of August 31, 2024, the 2021 Plan had 75,465 On July 26, 2023 and September 29, 2023, the Company’s Board of Directors and stockholders, respectively, approved the Novo Integrated Sciences, Inc. 2023 Equity Incentive Plan (the “2023 Plan”). Under the 2023 Plan, a total of 2,500,000 2,300,000 The following is a summary of stock options activity: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2022 216,423 21.50 2.53 $ 140,577 Granted 200,000 1.32 5.75 - Expired (45,000 ) - - - Exercised - Outstanding, August 31, 2023 371,423 $ 11.44 3.98 $ 16,000 Granted 200,000 0.78 - - Expired (33,000 ) - - - Exercised - - - - Outstanding, August 31, 2024 538,423 $ 7.17 3.42 $ - Exercisable, August 31, 2024 538,423 $ 7.17 3.42 $ - The exercise price for stock options outstanding and exercisable at August 31, 2024: Schedule of Options Outstanding and Exercisable Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 22,715 13.3 22,715 13.3 21,700 16 21,700 16 4,800 18.7 4,800 18.7 77,500 30 77,500 30 7,260 38 7,260 38 500 50 500 50 3,948 19 3,948 19 200,000 1.32 200,000 1.32 200,000 0.78 200,000 0.78 538,423 538,423 For options granted during the year ended August 31, 2023 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 1.32 1.32 For options granted during the year ended August 31, 2022 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 13.72 14.24 18.01 19.00 The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $ 147,656 385,335 nil The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows for the options granted during the year ended August 31, 2024 and 2023: Schedule of Fair Value of Options Granted by Using Valuation Assumptions 2024 2023 Risk-free interest rate 4.01 % 3.74 % Expected life of the options 6 6 Expected volatility 246 % 254 % Expected dividend yield - % 0 % Warrants The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2022 844,526 24.18 3.50 $ - Granted 1,077,661 1.39 3.51 Forfeited - Exercised (1,115,933 ) Outstanding, August 31, 2023 806,254 12.05 3.71 $ 106,960 Granted - Forfeited - Exercised (518,061 ) Outstanding, August 31, 2024 288,193 30.46 2.71 $ - Exercisable, August 31, 2024 288,193 The exercise price for warrants outstanding at August 31, 2024: Schedule of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 261,193 $ 33.50 27,000 1.00 - - 288,193

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Aug. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 – Income Taxes The Company’s Canadian subsidiaries are subject to the income tax laws of the Province of Ontario and the country of Canada. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of August 31, 2024 and 2023 based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model. The current and deferred income tax expenses for the years ended August 31, 2024 and 2023 were $ nil A reconciliation of the differences between the effective and statutory income tax rates are as follows: Schedule of Effective and Statutory Income Tax Rates Year Ended August 31, 2024 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (4,647,448 ) $ (11,519,296 ) $ (16,166,744 ) Expected income tax benefit (1,231,573 ) -26.5 % (3,110,210 ) -27.0 % (4,341,783 ) Stock based compensation - 0.0 % (24,159 ) 0.8 % 233,800 Change in valuation allowance 1,231,573 26.5 % 3,134,369 27.8 % 4,365,942 $ - 0.0 % $ - 0.0 % $ - 0.0 % Year Ended August 31, 2023 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (3,515,747 ) $ (9,698,805 ) $ (13,214,552 ) Expected income tax benefit (931,672 ) -26.5 % (2,618,677 ) -27.0 % (3,550,349 ) Stock based compensation - 0.0 % 233,800 9.0 % 233,800 Change in valuation allowance 931,672 26.5 % 2,384,877 18 % 3,316,549 $ - 0.0 % $ - 0.0 % $ - 0.0 % At August 31, 2024 and 2023, the significant components of the deferred tax asset and liability are summarized below: Schedule of the Deferred Tax Assets 2024 2023 Deferred tax asset: Net operating loss carryforwards $ 20,205,889 $ 15,839,947 Total deferred tax asset 20,205,889 15,839,947 Less: valuation allowance (20,205,889 ) (15,839,947 ) Total deferred tax asset - - Deferred tax liability: Intangible assets (1,395,571 ) (1,400,499 ) Total deferred tax liability (1,395,571 ) (1,400,499 ) Net deferred tax liability $ (1,395,571 ) $ (1,400,499 ) The valuation allowance for the years ended August 31, 2024 and 2023 increased as a result of the Company generating additional net operating losses. The Company has recorded as of August 31, 2024 and 2023 a valuation allowance of $ 20,205,889 15,839,947 The Company conducts an analysis of its tax positions and has concluded that it has no uncertain tax positions as of August 31, 2024 and 2023. As of August 31, 2023, the Company has net operating loss carry-forward of approximately $ 12,276,498

Acquisitions

Acquisitions	12 Months Ended
Acquisitions	Aug. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions	Note 16 – Acquisitions Acquisition of Businesses Joint Venture MiTelemed+ 50/50 Joint Venture with EK-Tech Solutions, Inc. On October 8, 2021, the Company and NHL completed a Joint Venture Agreement (the “MiTelemed+ JV”) with EK-Tech Solutions Inc. (“EK-Tech”) to establish the joint venture company MiTelemed+ Inc., an Ontario province Canada corporation (“MiTelemed+”), to operate, support, and expand access and functionality of EK-Tech’s enhanced proprietary Telehealth platform. At closing, EK-Tech contributed all intellectual property, source code, and core data of the iTelemed platform, valued at CAD$ 1,500,000 185,000 Mullins Asset Purchase Agreement On November 17, 2021, the Company entered into that certain Asset Purchase Agreement (the “Mullins APA”), dated as of November 17, 2021, by and between the Company and Terence Mullins. Pursuant to the terms of the Mullins APA, Mr. Mullins agreed to sell, and the Company agreed to purchase, all of Mr. Mullins’ right, title and interest in and to certain assets (the “Mullins IP Assets”), in exchange for a purchase price of CAD$ 2,500,000 1,990,250 (a) CAD$ 2,000,000 1,592,200 (b) CAD$ 500,000 398,050 11,883 All shares issued or allotted under the terms and conditions of the Mullins APA are calculated at a value of $ 33.50 15.90 755,701 188,925 The amounts assigned to assets acquired are provisional. Therefore, this may result in future adjustments to the provisional amounts as information is obtained about facts and circumstances that existed at the acquisition date. In addition, the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales reported through the Company or any of its wholly owned subsidiaries for a period equal to the commercial validity of the intellectual property. Terragenx Share Exchange Agreement On November 17, 2021, the Company and NHL, a wholly owned subsidiary of the Company, entered into that certain Share Exchange Agreement (the “Terra SEA”), dated as of November 17, 2021, by and among the Company, NHL, Terragenx Inc. (“Terra”), TMS Inc. (“TMS”), Shawn Mullins, Claude Fournier, and The Coles Optimum Health and Vitality Trust (“COHV” and collectively with TMS, Mr. Mullins and Mr. Fournier, the “Terra Shareholders”). Collectively, the Terra Shareholders owned 91% Pursuant to the terms of the Terra SEA, NHL agreed to purchase from the Terra Shareholders, and the Terra Shareholders agreed to sell to NHL, the Terra Purchased Shares on the closing date, in exchange for payment by NHL of the purchase price (the “Purchase Price”) of CAD$ 500,000 398,050 33.50 The Exchange closed on November 17, 2021. At the closing of the Exchange, (i) the Terra Shareholders transferred to NHL a total of 910 91% 100 11,883 91% In addition, the Company will issue 50,000 15.90 983,925 A summary of the purchase price allocation for Terra at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 29,291 Inventory 42,273 Prepaid expenses and other current assets 398 Property and equipment 66,759 Intangible assets 1,179,361 Accounts payable and accrued expenses (189,080 ) CEBA loan (47,766 ) Minority interest (97,311 ) Purchase price $ 983,925 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 983,925 $ 983,925 Share Exchange Agreement to Acquire 50.1% On March 1, 2022, the Company and NHL completed a Share Exchange Agreement (the “1285 SEA”) with 12858461 Canada Corp. (“1285”), a Canada federal corporation in the business of providing clinic-based physiotherapy and related ancillary services and products, and Prashant A. Jani, a Canadian citizen and sole shareholder of 1285 (the “1285 Shareholder”), to acquire 50.1% 68,000 1,700 40.00 This acquisition was considered an acquisition of a business under ASC 805. A summary of the purchase price allocation for 1285 at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 7,629 Accounts receivable 2,754 Property and equipment 8,813 Goodwill 602 Intangible assets 31,101 Minority interest (25,401 ) Purchase price $ 25,500 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 25,500 $ 25,500 Asset Purchase Agreement with Poling Taddeo Hovius Physiotherapy Professional Corp., operating as Fairway Physiotherapy and Sports Injury Clinic On March 1, 2022, the Company and NHL completed an Asset Purchase Agreement (the “PTHPC APA”) with Poling Taddeo Hovius Physiotherapy Professional Corp. (“PTHPC”), operating a clinic-based physiotherapy, rehabilitative, and related ancillary services and products business known as Fairway Physiotherapy and Sports Injury Clinic (“FAIR”), and Jason Taddeo, a Canadian citizen and the sole shareholder of PTHPC (the “PTHPC Shareholder”), Under the terms and conditions of the PTHPC APA, PTHPC agreed to sell, assign and transfer to NHL, free and clear of all encumbrances, other than permitted encumbrances, and NHL agreed to purchase from PTHPC all of PTHPC’s right, title and interest in and to all of its assets related to FAIR and the FAIR Business, with the exception of certain limited exclusions, and the rights, privileges, claims and properties of any kind whatsoever that are related thereto, whether owned or leased, real or personal, tangible or intangible, of every kind and description and wheresoever situated. Under the terms and conditions of the PTHPC APA, the purchase price is $ 627,000 15,675 40.00 This acquisition was considered an acquisition of a business under ASC 805. A summary of the purchase price allocation for PTHPC at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 18,383 Accounts receivable 44,289 Prepaid expenses and other current assets 11,292 Property and equipment 9,475 Intangible asset 151,686 Purchase price $ 235,125 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 235,125 $ 235,125 Effective April 1, 2024, Taddeo Physiotherapy Professional Corporation (TPPC) formerly Poling Taddeo Hovius Physiotherapy Professional Corp. have terminated the relationship with the Company as the terms of the Asset Purchase Agreement signed in the year 2022 were not met. Membership Interest Purchase Agreement with Clinical Consultants International LLC On March 17, 2022, the Company entered into a Membership Interest Purchase Agreement (the “CCI Agreement”) by and among the Company, CCI, each of the members of CCI (the “CCI Members”), and Dr. Joseph Chalil as the representative of the CCI Members. Pursuant to the terms of the CCI Agreement, among other things, the CCI Members will sell and assign to the Company all of their membership interests of CCI, in exchange for a total of 80,000 100% 80,000 This CCI Acquisition was accounted for as an asset acquisition, as substantially all of the fair value of the assets being acquired under the arrangement was concentrated in the customer relationships. Accordingly, the $ 1,704,000 1,701,814 A summary of the purchase price allocation for CCI at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 2,186 Intangible asset 1,701,814 Purchase price $ 1,704,000 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock 1,704,000 $ 1,704,000

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Aug. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 17 – Commitments and Contingencies Litigation The Company is party to certain legal proceedings from time to time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our condensed consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s unaudited condensed consolidated financial position as of August 31, 2024, results of operations, cash flows or liquidity of the Company.

Segment Reporting

Segment Reporting	12 Months Ended
Segment Reporting	Aug. 31, 2024
Segment Reporting [Abstract]
Segment Reporting	Note 18 – Segment Reporting ASC Topic 280, Segment Reporting The following tables summarize the Company’s segment information for the years ended August 31, 2024 and 2023: Schedule of Segment Reporting Information 2024 2023 Years Ended August 31, 2024 2023 Sales Healthcare services $ 8,297,530 $ 8,226,674 Product Sales 4,918,577 4,335,645 Corporate 78,250 9,700 Sales $ 13,294,357 $ 12,572,019 Gross profit Healthcare services $ 3,103,780 $ 2,998,315 Product Sales 2,560,474 1,944,701 Corporate 78,250 9,699 Gross profit $ 5,742,504 $ 4,952,715 Loss from operations Healthcare services $ (397,316 ) $ (413,670 ) Product Sales (3,032,650 ) (2,958,225 ) Corporate (6,646,332 ) (5,181,267 ) Income (loss) from operations $ (10,076,298 ) $ (8,553,162 ) Depreciation and amortization Healthcare services $ 120,327 $ 132,539 Product Sales 1,023,424 1,052,406 Corporate 1,117,768 1,117,809 Depreciation and amortization $ 2,261,519 $ 2,302,754 Capital expenditures Healthcare services $ - $ - Product Sales 5,034 49,224 Corporate - - Capital expenditures $ 5,034 $ 49,224 Interest expenses Healthcare services $ 82,943 $ 92,327 Product Sales 7,628 55,441 Corporate 561,827 212,803 Interest expenses $ 652,398 $ 360,571 Net loss Healthcare services $ (996,293 ) $ (496,970 ) Product Sales (4,013,231 ) (3,193,859 ) Corporate (11,119,046 ) (9,578,615 ) Net loss $ (16,128,570 ) $ (13,269,444 ) Total assets Healthcare services $ 4,759,470 $ 5,158,851 Product Sales 16,366,290 17,993,652 Corporate 11,015,516 12,410,544 $ 32,141,276 $ 35,563,047 Accounts receivable Healthcare services $ 724,624 $ 697,440 Product Sales 1,175,499 765,388 Corporate 16,696 4,200 $ 1,916,819 $ 1,467,028 Intangible assets Healthcare services $ 14,553 $ 120,163 Product Sales 2,850,617 3,818,313 Corporate 10,504,698 12,280,063 $ 13,369,868 $ 16,218,539 Goodwill Healthcare services $ 259,776 $ 520,821 Product Sales 6,294,697 7,061,662 Corporate - - $ 6,554,473 $ 7,582,483

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Aug. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 19 – Subsequent Events Registration Statement on Form S-8 On September 23, 2024, the Company filed a registration statement on Form S-8 (File No. 333-282277) registering 2,500,000 Streeterville Common Stock Issuance On October 8, 2024, Streeterville notified the Company that it would redeem $ 950,000 950,000 142,500 15 950,000 142,500 675,724 142,500 6,579,657.54 Termination of Ophir Agreement On October 17, 2024, the Ophir Agreement was terminated. On such date, the Successor Receiver filed notice with the Court that the Successor Receiver canceled, without objection by the Company, the Ophir Agreement. Resignation of Robert Oliva On October 25, 2024, Mr. Oliva resigned as President of the Company. His resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Nasdaq Delisting On November 4, 2024, the Company received a letter from Nasdaq indicating that the Company’s common stock would be delisted from Nasdaq and trading in the Company’s common stock would be suspended at the open of trading on November 6, 2024. Beginning at the open of trading on November 6, 2024, trading of the Company’s common stock continued on the OTC Market’s Pink Current Information tier under the symbol “NVOS.” Resignation of Robert Mattacchione as Chief Executive Officer On November 7, 2024, Mr. Mattacchione resigned as the Company’s Chief Executive Officer , effective 90 days following the notification date (i.e. effective February 5, 2025). The 90-day notice period is intended to provide the Company with a fluid transition and to allow the Company time to appoint a suitable replacement. Following the 90-day transition period, Mr. Mattacchione intends to continue to serve as (i) the Company’s Chairman of the Board, and (ii) Chairman of NHL, a wholly owned subsidiary of the Company. Approval of Reverse Stock Split On November 22, 2024, stockholders approved the amendment of the Company’s articles of incorporation, as amended, to effectuate a reverse stock split of the Company’s outstanding shares of common stock at a ratio of no less than 1-for-10 1-for-30

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Aug. 31, 2024
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to the going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91 50.1 80 70 All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation.
Noncontrolling Interest	Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and comprehensive loss.
Cash Equivalents	Cash Equivalents For the purpose of the consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of August 31, 2024 and 2023, the allowance for uncollectible accounts receivable was $ 1,273,596 864,215 10 nil
Inventory	Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of August 31, 2024 and 2023, the Company’s allowance for slow moving or obsolete inventory was $ nil nil
Other Receivables	Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the years ended August 31, 2024 and 2023, the Company wrote off $ nil nil
Property and Equipment	Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful Lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5
Leases	Leases The Company applies the provisions of ASC Topic 842, Leases
Long-Lived Assets	Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment
Intangible Assets	Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at August 31, 2024 and 2023, the Company believes there was $ 1,726,776 nil impairment of assets
Right-of-use Assets	Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12
Goodwill	Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. As of August 31, 2024, the Company performed the required impairment reviews and determined that an impairment charge of $ 742,120 259,213 Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2022 190,678 125,088 221,188 7,288,307 583 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 184,750 121,196 214,310 7,061,662 565 7,582,483 Beginning balance 184,750 121,196 214,310 7,061,662 565 7,582,483 Impairment of goodwill (92,375 ) (60,598 ) (106,240 ) (742,120 ) - (1,001,333 ) Foreign currency translation adjustment (2,461 ) (1,614 ) (2,830 ) (19,770 ) (2 ) (26,677 ) Balance, August 31, 2024 89,914 58,984 105,240 6,299,772 563 6,554,473 Ending balance 89,914 58,984 105,240 6,299,772 563 6,554,473
Fair Value of Financial Instruments	Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, and current liabilities, including accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of August 31, 2024 and 2023, respectively, the Company did not identify any financial assets and liabilities required to be presented on the consolidated balance sheet at fair value, except for contingent liability which is carried at fair value using Level 1 inputs and derivative liability which is carried at fair value using Level 3 inputs.
Derivative Financial Instruments	Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives.
Revenue Recognition	Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of ASU No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying consolidated balance sheets. Sales returns and allowances were insignificant for the years ended August 31, 2024 and 2023. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.
Stock-Based Compensation	Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation
Basic and Diluted Earnings Per Share	Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 826,616 1,777,678 24,608,975 1,700 Due to the net loss incurred potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented.
Foreign Currency Transactions and Comprehensive Income	Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gain of $ 1,744,627 922,609
Consolidated Statements of Cash Flows	Consolidated Statements of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.
Segment Reporting	Segment Reporting ASC Topic 280, Segment Reporting
Reclassifications	Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. In December 2021, the FASB issued an update to ASU No. 2016-13 the Current Expected Credit Losses (CECL) standard (ASC 326), which is designed to provide greater transparency and understanding of credit risk by incorporating estimated, forward-looking data when measuring lifetime Estimated Credit Losses (ECL) and requires enhanced financial statement disclosures. This guidance was adopted during the year ended August 31, 2024, and as a result an increase in the allowance is recorded. In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures In March 2020, the FASB issued ASU No. 2020-04 providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020, could be applied through December 31, 2022. In December 2022, the FASB issued No 2022-06 extending the sunset date of the relief provided under ASU No. 2020-04 to December 31, 2024. The ASU has not impacted these consolidated financial statements. The Company has various contracts that reference LIBOR and is assessing how this standard may be applied to specific contract modifications through December 31, 2024. Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	12 Months Ended
Organization and Basis of Presentation (Tables)	Aug. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Foreign Currency Translation, Exchange Rate Used	Schedule of Foreign Currency Translation, Exchange Rate Used August 31, 2024 August 31, 2023 Period end: CAD to USD exchange rate $ 0.7364 $ 0.7390 Average period: CAD to USD exchange rate $ 0.7349 $ 0.7426

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Aug. 31, 2024
Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Assets	Schedule of Estimated Useful Lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5
Schedule of Intangible Assets Amortized Estimated Useful Lives	The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7
Schedule of Changes in Goodwill	Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2022 190,678 125,088 221,188 7,288,307 583 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 184,750 121,196 214,310 7,061,662 565 7,582,483 Beginning balance 184,750 121,196 214,310 7,061,662 565 7,582,483 Impairment of goodwill (92,375 ) (60,598 ) (106,240 ) (742,120 ) - (1,001,333 ) Foreign currency translation adjustment (2,461 ) (1,614 ) (2,830 ) (19,770 ) (2 ) (26,677 ) Balance, August 31, 2024 89,914 58,984 105,240 6,299,772 563 6,554,473 Ending balance 89,914 58,984 105,240 6,299,772 563 6,554,473

Inventory (Tables)

Inventory (Tables)	12 Months Ended
Inventory (Tables)	Aug. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory at August 31, 2024 and 2023 consisted of the following: Schedule of Inventory 2024 2023 Raw materials $ 227,471 $ 388,391 Work in process 225,089 81,696 Finished Goods 548,182 636,896 Inventory Gross 1,000,742 1,106,983 Allowance for slow moving and obsolete inventory - - Inventory, net $ 1,000,742 $ 1,106,983

Accounts Receivables, net (Tabl

Accounts Receivables, net (Tables)	12 Months Ended
Accounts Receivables, net (Tables)	Aug. 31, 2024
Receivables [Abstract]
Schedule of Accounts Receivable, Net	Accounts receivables, net at August 31, 2024 and 2023 consisted of the following: Schedule of Accounts Receivable, Net 2024 2023 Trade receivables $ 3,173,068 $ 2,223,243 Amounts earned but not billed 17,347 108,000 Accounts receivables gross 3,190,415 2,331,243 Allowance for doubtful accounts (1,273,596 ) (864,215 ) Accounts receivable, net $ 1,916,819 $ 1,467,028

Other Receivables (Tables)

Other Receivables (Tables)	12 Months Ended
Other Receivables (Tables)	Aug. 31, 2024
Receivables [Abstract]
Schedule of Other Receivables	Other receivables at August 31, 2024 and 2023 consisted of the following: Schedule of Other Receivables 2024 2023 Advance to corporation; accrues interest at 12 December 31, 2024 73,640 73,900 Advance to corporation; accrues interest at 12 December 31, 2024 646,302 534,386 Advance to corporation; accrues interest at 10 December 31, 2024 515,481 443,298 Total other receivables 1,235,423 1,051,584 Current portion (1,235,423 ) (1,051,584 ) Long-term portion $ - $ -

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Aug. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment at August 31, 2024 and 2023 consisted of the following: Schedule of Property and Equipment 2024 2023 Land $ 441,840 $ 443,400 Building 3,313,800 3,325,500 Leasehold improvements 764,091 841,371 Clinical equipment 1,908,833 1,916,681 Computer equipment 38,430 33,504 Office equipment 44,404 44,502 Furniture and fixtures 38,154 38,289 Property and Equipment gross 6,549,552 6,643,247 Accumulated depreciation (1,438,776 ) (1,253,209 ) Total $ 5,110,776 $ 5,390,038

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
Intangible Assets (Tables)	Aug. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets at August 31, 2024 and 2023 consisted of the following: Schedule of Intangible Assets 2024 2023 Land use rights $ 10,968,933 $ 11,573,321 Intellectual property 7,331,114 7,497,746 Customer relationships 2,145,917 2,291,058 Brand names 1,921,636 1,928,421 Finite lived intangible assets, gross 22,367,600 23,290,546 Accumulated amortization (8,997,732 ) (7,072,007 ) Total $ 13,369,868 $ 16,218,539
Schedule of Expected Amortization Expense of intangible Assets	Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of intangible Assets Years Ending August 31, 2025 $ 2,125,036 2026 1,310,941 2027 1,094,292 2028 759,115 2029 219,379 Thereafter 7,861,105 Total $ 13,369,868

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
Accrued Expenses (Tables)	Aug. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses at August 31, 2024 and 2023 consisted of the following: Schedule of Accrued Expenses 2023 2023 Accrued liabilities $ 1,084,148 $ 961,897 Accrued payroll 268,772 236,218 Unearned revenue 239,368 35,434 Accrued expense $ 1,592,288 $ 1,233,549

Government Loans and Note Pay_2

Government Loans and Note Payable and Government Subsidy (Tables)	12 Months Ended
	Aug. 31, 2024
Government Loans And Note Payable And Government Subsidy
Schedule of Governmental Loans and Note Payable	Governmental loans and note payable at August 31, 2024 and 2023 consisted of the following: Schedule of Governmental Loans and Note Payable 2024 2023 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A) 88,770 88,680 Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75 190 40,320 40,320 Note payable dated December 3, 2018; accrues interest at 4.53 4,000 28,592 28,693 Note payable received May 25, 2023 accruing interest at 18 - 73,900 Note payable received May 10, 2023 accruing interest at 15 - 110,850 Total government loans and notes payable 157,682 342,443 Less current portion (45,681 ) (277,405 ) Long-term portion $ 112,001 $ 65,038 (A) The Government of Canada launched the Canada Emergency Business Account (“CEBA”) loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained a CAD$ 80,000 59,120 January 18, 2024 25 75 5 60,000 20,000 29,332
Schedule of Future Maturities Outstanding of Government Loans and Notes Payable	Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of Government Loans and Notes Payable Years Ending August 31, 2025 $ 45,681 2026 45,681 2027 21,925 2028 8,172 2029 3,646 Thereafter 32,577 Total $ 157,682

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Aug. 31, 2024
Leases
Schedule of Lease Related Assets and Liabilities	The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of August 31, 2024 and 2023: Schedule of Lease Related Assets and Liabilities 2024 2023 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 1,691,309 $ 1,983,898 Total lease assets $ 1,691,309 $ 1,983,898 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 403,291 $ 415,392 Noncurrent liabilities Operating lease liability Long-term operating lease liability 1,440,367 1,693,577 Total lease liability $ 1,843,658 $ 2,108,969
Schedule of Lease Obligations	Lease obligations at August 31, 2024 consisted of the following: Schedule of Lease Obligations Years Ending August 31, 2025 $ 547,571 2026 547,393 2027 510,676 2028 293,723 2029 173,588 Thereafter 167,269 Total payments 2,240,220 Amount representing interest (396,562 ) Lease obligation, net 1,843,658 Less lease obligation, current portion (403,291 ) Lease obligation, long-term portion $ 1,440,367
Schedule of Finance Leases	The net book value of equipment under finance leases included in property and equipment on the accompanying balance sheet at August 31, 2024 is as follows: Schedule of Finance Leases Cost $ 209,457 Accumulated amortization (209,457 ) Net book value $ -
Schedule of Future Minimum Lease Payments	Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Years Ending August 31, 2025 $ 4,420 Total payments 4,420 Amount representing interest (66 ) Lease obligation, net 4,354 Less lease obligation, current portion (4,354 ) Lease obligation, long-term portion $ -

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
Stockholders’ Equity (Tables)	Aug. 31, 2024
Equity [Abstract]
Schedule of Stock Option Activity	The following is a summary of stock options activity: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2022 216,423 21.50 2.53 $ 140,577 Granted 200,000 1.32 5.75 - Expired (45,000 ) - - - Exercised - Outstanding, August 31, 2023 371,423 $ 11.44 3.98 $ 16,000 Granted 200,000 0.78 - - Expired (33,000 ) - - - Exercised - - - - Outstanding, August 31, 2024 538,423 $ 7.17 3.42 $ - Exercisable, August 31, 2024 538,423 $ 7.17 3.42 $ -
Schedule of Options Outstanding and Exercisable	The exercise price for stock options outstanding and exercisable at August 31, 2024: Schedule of Options Outstanding and Exercisable Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 22,715 13.3 22,715 13.3 21,700 16 21,700 16 4,800 18.7 4,800 18.7 77,500 30 77,500 30 7,260 38 7,260 38 500 50 500 50 3,948 19 3,948 19 200,000 1.32 200,000 1.32 200,000 0.78 200,000 0.78 538,423 538,423
Schedule of Fair Value of Options Granted by Using Valuation Assumptions	The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows for the options granted during the year ended August 31, 2024 and 2023: Schedule of Fair Value of Options Granted by Using Valuation Assumptions 2024 2023 Risk-free interest rate 4.01 % 3.74 % Expected life of the options 6 6 Expected volatility 246 % 254 % Expected dividend yield - % 0 %
Schedule of Warrant Activity	The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2022 844,526 24.18 3.50 $ - Granted 1,077,661 1.39 3.51 Forfeited - Exercised (1,115,933 ) Outstanding, August 31, 2023 806,254 12.05 3.71 $ 106,960 Granted - Forfeited - Exercised (518,061 ) Outstanding, August 31, 2024 288,193 30.46 2.71 $ - Exercisable, August 31, 2024 288,193
Schedule of Warrants Outstanding	The exercise price for warrants outstanding at August 31, 2024: Schedule of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 261,193 $ 33.50 27,000 1.00 - - 288,193

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Aug. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Effective and Statutory Income Tax Rates	A reconciliation of the differences between the effective and statutory income tax rates are as follows: Schedule of Effective and Statutory Income Tax Rates Year Ended August 31, 2024 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (4,647,448 ) $ (11,519,296 ) $ (16,166,744 ) Expected income tax benefit (1,231,573 ) -26.5 % (3,110,210 ) -27.0 % (4,341,783 ) Stock based compensation - 0.0 % (24,159 ) 0.8 % 233,800 Change in valuation allowance 1,231,573 26.5 % 3,134,369 27.8 % 4,365,942 $ - 0.0 % $ - 0.0 % $ - 0.0 % Year Ended August 31, 2023 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (3,515,747 ) $ (9,698,805 ) $ (13,214,552 ) Expected income tax benefit (931,672 ) -26.5 % (2,618,677 ) -27.0 % (3,550,349 ) Stock based compensation - 0.0 % 233,800 9.0 % 233,800 Change in valuation allowance 931,672 26.5 % 2,384,877 18 % 3,316,549 $ - 0.0 % $ - 0.0 % $ - 0.0 %
Schedule of the Deferred Tax Assets	At August 31, 2024 and 2023, the significant components of the deferred tax asset and liability are summarized below: Schedule of the Deferred Tax Assets 2024 2023 Deferred tax asset: Net operating loss carryforwards $ 20,205,889 $ 15,839,947 Total deferred tax asset 20,205,889 15,839,947 Less: valuation allowance (20,205,889 ) (15,839,947 ) Total deferred tax asset - - Deferred tax liability: Intangible assets (1,395,571 ) (1,400,499 ) Total deferred tax liability (1,395,571 ) (1,400,499 ) Net deferred tax liability $ (1,395,571 ) $ (1,400,499 )

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
Acquisitions (Tables)	Aug. 31, 2024
Terragenx [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 29,291 Inventory 42,273 Prepaid expenses and other current assets 398 Property and equipment 66,759 Intangible assets 1,179,361 Accounts payable and accrued expenses (189,080 ) CEBA loan (47,766 ) Minority interest (97,311 ) Purchase price $ 983,925
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 983,925 $ 983,925
Canada Corp [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 7,629 Accounts receivable 2,754 Property and equipment 8,813 Goodwill 602 Intangible assets 31,101 Minority interest (25,401 ) Purchase price $ 25,500
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 25,500 $ 25,500
Poling Taddeo Hovius Physiotherapy Professional Corp [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 18,383 Accounts receivable 44,289 Prepaid expenses and other current assets 11,292 Property and equipment 9,475 Intangible asset 151,686 Purchase price $ 235,125
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 235,125 $ 235,125
Clinical Consultants International LLC [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 2,186 Intangible asset 1,701,814 Purchase price $ 1,704,000
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock 1,704,000 $ 1,704,000

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
Segment Reporting (Tables)	Aug. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The following tables summarize the Company’s segment information for the years ended August 31, 2024 and 2023: Schedule of Segment Reporting Information 2024 2023 Years Ended August 31, 2024 2023 Sales Healthcare services $ 8,297,530 $ 8,226,674 Product Sales 4,918,577 4,335,645 Corporate 78,250 9,700 Sales $ 13,294,357 $ 12,572,019 Gross profit Healthcare services $ 3,103,780 $ 2,998,315 Product Sales 2,560,474 1,944,701 Corporate 78,250 9,699 Gross profit $ 5,742,504 $ 4,952,715 Loss from operations Healthcare services $ (397,316 ) $ (413,670 ) Product Sales (3,032,650 ) (2,958,225 ) Corporate (6,646,332 ) (5,181,267 ) Income (loss) from operations $ (10,076,298 ) $ (8,553,162 ) Depreciation and amortization Healthcare services $ 120,327 $ 132,539 Product Sales 1,023,424 1,052,406 Corporate 1,117,768 1,117,809 Depreciation and amortization $ 2,261,519 $ 2,302,754 Capital expenditures Healthcare services $ - $ - Product Sales 5,034 49,224 Corporate - - Capital expenditures $ 5,034 $ 49,224 Interest expenses Healthcare services $ 82,943 $ 92,327 Product Sales 7,628 55,441 Corporate 561,827 212,803 Interest expenses $ 652,398 $ 360,571 Net loss Healthcare services $ (996,293 ) $ (496,970 ) Product Sales (4,013,231 ) (3,193,859 ) Corporate (11,119,046 ) (9,578,615 ) Net loss $ (16,128,570 ) $ (13,269,444 ) Total assets Healthcare services $ 4,759,470 $ 5,158,851 Product Sales 16,366,290 17,993,652 Corporate 11,015,516 12,410,544 $ 32,141,276 $ 35,563,047 Accounts receivable Healthcare services $ 724,624 $ 697,440 Product Sales 1,175,499 765,388 Corporate 16,696 4,200 $ 1,916,819 $ 1,467,028 Intangible assets Healthcare services $ 14,553 $ 120,163 Product Sales 2,850,617 3,818,313 Corporate 10,504,698 12,280,063 $ 13,369,868 $ 16,218,539 Goodwill Healthcare services $ 259,776 $ 520,821 Product Sales 6,294,697 7,061,662 Corporate - - $ 6,554,473 $ 7,582,483

Schedule of Foreign Currency Tr

Schedule of Foreign Currency Translation, Exchange Rate Used (Details)	Aug. 31, 2024	Aug. 31, 2023
Period End [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7364	0.7390
Average Period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7349	0.7426

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details Narrative) - USD ($)				12 Months Ended
	Nov. 07, 2023	May 09, 2017	Apr. 25, 2017	Aug. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock split	1-for-10 reverse stock split
Parent Company [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock issued in connection with reverse merger transaction		$ 6,904
Share Exchange Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of restricted shares of common stock, shares				73,767
Share Exchange Agreement [Member] \| NHL [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of restricted shares of common stock, shares			1,677,974
Percentage of common stock issued and outstanding			85%

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Assets (Details)	Aug. 31, 2024
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	30 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years

Schedule of Intangible Assets A

Schedule of Intangible Assets Amortized Estimated Useful Lives (Details)	Aug. 31, 2024
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	50 years
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	5 years
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years

Schedule of Changes in Goodwill

Schedule of Changes in Goodwill (Details) - USD ($)	12 Months Ended
Schedule of Changes in Goodwill (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Beginning balance	$ 7,582,483	$ 7,825,844
Foreign currency translation adjustment	(26,677)	(243,361)
Impairment of goodwill	(1,001,333)
Ending balance	6,554,473	7,582,483
APKA Health, Inc. [Member]
Beginning balance	184,750	190,678
Foreign currency translation adjustment	(2,461)	(5,928)
Impairment of goodwill	(92,375)
Ending balance	89,914	184,750
EFL [Member]
Beginning balance	121,196	125,088
Foreign currency translation adjustment	(1,614)	(3,892)
Impairment of goodwill	(60,598)
Ending balance	58,984	121,196
Rockland [Member]
Beginning balance	214,310	221,188
Foreign currency translation adjustment	(2,830)	(6,878)
Impairment of goodwill	(106,240)
Ending balance	105,240	214,310
Acenzia Inc [Member]
Beginning balance	7,061,662	7,288,307
Foreign currency translation adjustment	(19,770)	(226,645)
Impairment of goodwill	(742,120)
Ending balance	6,299,772	7,061,662
1285 Canada [Member]
Beginning balance	565	583
Foreign currency translation adjustment	(2)	(18)
Impairment of goodwill
Ending balance	$ 563	$ 565

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2024	Aug. 31, 2023
Allowance for uncollectible accounts receivable	$ 1,273,596	$ 864,215
Inventory
Other receivable written off
Impairment of intangible assets	$ 1,726,776
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]	Impairment of assets	Impairment of assets
Contract lease term	12 months
Goodwill impairment charge	$ 1,001,333
Foreign currency translation gain (loss)	$ 1,744,627	$ 922,609
Common Stock [Member]
Debt conversion, converted instrument, shares issued	24,608,975
Common Stock To Be Issued [Member]
Debt conversion, converted instrument, shares issued	1,700
Options or Warrants Outstanding [Member]
Potentially dilutive common stock options and warrants outstanding, shares	826,616	1,777,678
Acenzia Inc [Member]
Goodwill impairment charge	$ 742,120
NHL [Member]
Goodwill impairment charge	$ 259,213
Terragenx Inc [Member]
Ownership percentage	91%
1285 Canada [Member]
Ownership percentage	50.10%
Novo Healthnet Kemptville Centre, Inc [Member]
Ownership percentage	80%
Novo Earth Therapeutics Inc [Member]
Ownership percentage	70%
One Customer [Member]
Ownership percentage	10%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Related Party [Member] - USD ($)	12 Months Ended
	Aug. 31, 2024	Aug. 31, 2023
Related Party Transaction [Line Items]
Due to related parties	$ 356,928	$ 533,001
Debentures, related parties	913,598	916,824
Non Interest Bearing [Member]
Related Party Transaction [Line Items]
Due to related parties	275,351	451,137
16% Interest Rate [Member]
Related Party Transaction [Line Items]
Due to related parties		$ 21,267
Bearing interest rate	6%	6%
13.75% Interest Rate [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 81,577	$ 60,597
Bearing interest rate	13.75%	13.75%

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 227,471	$ 388,391
Work in process	225,089	81,696
Finished Goods	548,182	636,896
Inventory Gross	1,000,742	1,106,983
Allowance for slow moving and obsolete inventory
Inventory, net	$ 1,000,742	$ 1,106,983

Schedule of Accounts Receivable

Schedule of Accounts Receivable, Net (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Receivables [Abstract]
Trade receivables	$ 3,173,068	$ 2,223,243
Amounts earned but not billed	17,347	108,000
Accounts receivables gross	3,190,415	2,331,243
Allowance for doubtful accounts	(1,273,596)	(864,215)
Accounts receivable, net	$ 1,916,819	$ 1,467,028

Schedule of Other Receivables (

Schedule of Other Receivables (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 1,235,423	$ 1,051,584
Current portion	(1,235,423)	(1,051,584)
Long-term portion
Advance To Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	73,640	73,900
Advance To Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	646,302	534,386
Advance To Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 515,481	$ 443,298

Schedule of Other Receivables_2

Schedule of Other Receivables (Details) (Parenthetical)	12 Months Ended
Schedule of Other Receivables (Details) (Parenthetical)	Aug. 31, 2024	Aug. 31, 2023
Advance To Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12%	12%
Notes receivable due date	Dec. 31, 2024	Dec. 31, 2024
Advance To Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12%	12%
Notes receivable due date	Dec. 31, 2024	Dec. 31, 2024
Advance To Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	10%	10%
Notes receivable due date	Dec. 31, 2024	Dec. 31, 2024

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Property, Plant and Equipment [Line Items]
Property and Equipment gross	$ 6,549,552	$ 6,643,247
Accumulated depreciation	(1,438,776)	(1,253,209)
Total	5,110,776	5,390,038
Land [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	441,840	443,400
Building [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	3,313,800	3,325,500
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	764,091	841,371
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	1,908,833	1,916,681
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	38,430	33,504
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	44,404	44,502
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	$ 38,154	$ 38,289

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 259,510	$ 292,041

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 22,367,600	$ 23,290,546
Accumulated amortization	(8,997,732)	(7,072,007)
Total	13,369,868	16,218,539
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	10,968,933	11,573,321
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	7,331,114	7,497,746
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	2,145,917	2,291,058
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 1,921,636	$ 1,928,421

Schedule of Expected Amortizati

Schedule of Expected Amortization Expense of intangible Assets (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 2,125,036
2026	1,310,941
2027	1,094,292
2028	759,115
2029	219,379
Thereafter	7,861,105
Total	$ 13,369,868	$ 16,218,539

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)				12 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Dec. 17, 2019	Jan. 30, 2019	Jan. 07, 2019	Aug. 31, 2024	Aug. 31, 2023	Mar. 17, 2022	Mar. 01, 2022	Nov. 17, 2021	May 28, 2021	May 24, 2021
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets				$ 2,002,009	$ 2,010,713
Pro-Dip, LLC [Member] \| Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired				103,476	52,752					$ 455,752
Acenzia Inc [Member] \| Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired									$ 2,875,000
Acenzia Inc [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired									806,000
Acenzia Inc [Member] \| Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired									$ 2,115,000
Terragenx Inc [Member] \| Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired								$ 1,179,361
1285 Canada [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired							$ 31,101
Poling Taddeo Hovius Physiotherapy Professional Corp [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired							$ 151,686
Clinical Consultants International LLC [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired					317,314	$ 1,701,814
Joint Venture Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage joint venture description			Pursuant to the terms of the Joint Venture Agreement, as assigned to us, the parties will work in a joint venture relationship (“JV”) with the Company providing the finance, development and operation of the project, including sales, and Kainai providing the land and approvals for the development of the projects. Pursuant to the terms of the Joint Venture Agreement, (i) the Company has an 80% controlling interest and Kainai has a 20% interest in the JV; and (ii) the Company has sole discretion to identify the name and entity under which the JV will operate. The legal entity in which the JV will operate has not yet been identified or formed. The JV operations will primarily involve the production – including processing, packaging and sales of natural supplements derived from hemp derived cannabis oils. The joint venture will distribute to the Company and Kainai all net proceeds after debt and principal servicing and repayment allocation, as well as operating capital allotment, on a ratio equal to 80% to the Company and 20% to Kainai.
Intangible asset, useful life amortized over term			50 years
Joint Venture Agreement [Member] \| Ontario Ltd [Member]
Finite-Lived Intangible Assets [Line Items]
Number of restricted shares of common stock, shares		120,000
Number of restricted shares of common stock		$ 21,600,000
Payments to acquire land held for use				604,388	10,026,679
Asset Purchase Agreement [Member] \| Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Number of restricted shares of common stock, shares	80,000
Number of restricted shares of common stock	$ 5,248,000
Payments to acquire land held for use				$ 53,206	$ 1,858,179

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Payables and Accruals [Abstract]
Accrued liabilities	$ 1,084,148	$ 961,897
Accrued payroll	268,772	236,218
Unearned revenue	239,368	35,434
Accrued expense	$ 1,592,288	$ 1,233,549

Schedule of Governmental Loans

Schedule of Governmental Loans and Note Payable (Details) - USD ($)		Aug. 31, 2024	Aug. 31, 2023
Short-Term Debt [Line Items]
Total government loans and notes payable		$ 157,682	$ 342,443
Less current portion		(45,681)	(277,405)
Long-term portion		112,001	65,038
Notes Payable One [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable	[1]	88,770	88,680
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		40,320	40,320
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		28,592	28,693
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable			73,900
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable			$ 110,850

[1]The Government of Canada launched the Canada Emergency Business Account (“CEBA”) loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained a CAD$ 80,000 59,120 January 18, 2024 25 75 5 60,000 20,000 29,332

Schedule of Governmental Loan_2

Schedule of Governmental Loans and Note Payable (Details) (Parenthetical)	12 Months Ended
	Aug. 31, 2024 USD ($)	Aug. 31, 2024 CAD ($)	Aug. 31, 2023 USD ($)	Aug. 31, 2024 CAD ($)	Aug. 31, 2023 CAD ($)
Short-Term Debt [Line Items]
Default in repayment rate	75%	75%
Interest rate during fixed rate	5%			5%
Canada Emergency Business Account Loan [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Jan. 18, 2024	Jan. 18, 2024
Forgiveness percentage	25%	25%
Canada Emergency Business Account Loan [Member] \| Terragenx [Member]
Short-Term Debt [Line Items]
Notes payable	$ 29,332			$ 60,000
Repayment of debt		$ 20,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period	3.75%	3.75%	3.75%
Periodic payment	$ 190		$ 190
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period	4.53%	4.53%	4.53%
Periodic payment	$ 4,000		$ 4,000
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period	18%	18%	18%
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period	15%	15%	15%
Canada Emergency Business Account Loan [Member]
Short-Term Debt [Line Items]
Notes payable			$ 59,120		$ 80,000

Schedule of Future Maturities O

Schedule of Future Maturities Outstanding of Government Loans and Notes Payable (Details)	Aug. 31, 2024 USD ($)
Government Loans And Note Payable And Government Subsidy
2025	$ 45,681
2026	45,681
2027	21,925
2028	8,172
2029	3,646
Thereafter	32,577
Total	$ 157,682

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)																																12 Months Ended
Convertible Notes Payable (Details Narrative)	Oct. 08, 2024 USD ($)	May 20, 2024 USD ($)	Apr. 20, 2024 USD ($)	Apr. 08, 2024 USD ($)	Apr. 05, 2024 USD ($)	Mar. 20, 2024 USD ($)	Feb. 21, 2024 USD ($)	Feb. 20, 2024 USD ($)	Jan. 21, 2024 USD ($)	Jan. 20, 2024 USD ($)	Dec. 23, 2023 USD ($)	Dec. 21, 2023 USD ($) $ / shares shares	Dec. 20, 2023 USD ($)	Nov. 23, 2023 USD ($)	Nov. 21, 2023 USD ($)	Oct. 23, 2023 USD ($) shares	Oct. 21, 2023 USD ($)	Sep. 23, 2023 USD ($)	Sep. 21, 2023 USD ($)	Sep. 18, 2023 USD ($) shares	Aug. 24, 2023 USD ($) $ / shares shares	Aug. 23, 2023 USD ($)	Aug. 21, 2023 USD ($) shares	Jun. 20, 2023 USD ($) $ / shares shares	Mar. 21, 2023 USD ($) $ / shares shares	Feb. 24, 2023 shares	Feb. 23, 2023 USD ($) $ / shares shares	Jan. 23, 2023 USD ($)	Jun. 01, 2022 USD ($)	Dec. 14, 2021 USD ($) $ / shares shares	Nov. 17, 2021 USD ($) $ / shares shares	Aug. 31, 2024 USD ($) shares	Aug. 31, 2023 USD ($) shares	Aug. 31, 2022 USD ($)	Aug. 24, 2024 USD ($)	Oct. 20, 2023 USD ($)	Sep. 12, 2023 USD ($)	Jul. 20, 2023 USD ($)	Mar. 24, 2023 USD ($)
Debt amortized discount																																$ 6,574,862	$ 4,757,121
Aggregate Principal amount owed
Event of default description					The Company may prepay the Note at any time prior to the date that an Event of Default (as defined in the Streeterville Note) (each an “Event of Default”) occurs at an amount equal to 105% of the Outstanding Balance (as defined below). “Outstanding Balance” means the Streeterville Principal Sum then outstanding plus accrued and unpaid interest
Trigger effect description					The “Trigger Effect” means 20% of the Outstanding Balance upon the occurrence of any Major Trigger Event (as defined in the Streeterville Note) and 5% of the Outstanding Balance upon the occurrence of any Minor Trigger Event (as defined in the Streeterville Note). The Trigger Effect for any Minor Trigger Event may occur up to three times. Upon the occurrence of an Event of Default, additional interest will accrue from the date of the Event of Default at the rate equal to the lower of 22% per annum or the highest rate permitted by law.
Mast Hill Securities Purchase Agreement [Member]
Debt instrument, face value																					$ 580,778			$ 445,000			$ 573,000					445,000
Maturity date																								Jun. 20, 2024			Feb. 23, 2024
Debt instrument conversion price \| $ / shares												$ 1.11095									$ 1.11095			$ 1.75			$ 1.75
Exercise price of warrants or rights \| $ / shares																								$ 2.50			$ 2.50
Estimated value warrants																											$ 86,327
Debt instrument, unamortized discount																								$ 44,500			57,300
Loan fees																								$ 39,904			70,465
Debt amortized discount																											$ 297,055						$ 297,055
Convertible notes payable																			$ 4,535				$ 4,535													$ 4,389		$ 4,243
Debt conversion, converted instrument, shares issued \| shares												457,128									522,777												522,777
Debt instrument, interest rate, effective percentage																								12%			12%
Class of warrant or right, number of shares \| shares																								1,772,045			2,772,045
Accrued liabilities		$ 77,661	$ 77,661			$ 77,661		$ 44,500		$ 44,500	$ 100,000		$ 44,500	$ 100,000		$ 57,300		$ 57,300				$ 57,300						$ 100,000
Percentage of stock price trigger																								85%			85%
Administrative fees expense																								$ 750			$ 750
Variable interest, percentage rate																								125%			125%
Number of restricted shares \| shares																138,703				53,567				74,167		95,500
Percentage of issued and outstanding common stock																											19.99%
Debt instrument aggregate principal amount												$ 454,071									$ 573,000												$ 573,000		$ 573,000
Accrued interest																																9,071	6,028
Other fees																																	1,750
Proceeds from warrant exercises																				$ 573,000												573,000
Debt instrument, effective conversion price \| $ / shares																								$ 1.150
Share price \| $ / shares																								$ 1.535
Beneficial conversion feature																								$ 97,978
Original issue discount																								44,500
Payments for repurchase of warrants																								400,500
Estimated value of the warrants																								$ 77,856
Mast Hill Securities Purchase Agreement [Member] \| Maximum [Member]
Class of warrant or right, number of shares \| shares																								77,662			100,000
Variable interest, percentage rate																											16%
Mast Hill Note and Mast Hill Warrant [Member]
Debt instrumment converted amount																											$ 515,700
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt instrument, face value																									$ 573,000
Maturity date																									Mar. 21, 2024
Debt instrument conversion price \| $ / shares																									$ 1.75
Exercise price of warrants or rights \| $ / shares																									$ 2.50
Estimated value warrants																									$ 93,811
Debt instrument, unamortized discount																									57,300								190,209
Loan fees																									35,628
Debt amortized discount																									$ 342,938								152,729
Debt instrument, interest rate, effective percentage																									12%
Class of warrant or right, number of shares \| shares																									1,000,000
Accrued liabilities							$ 100,000		$ 100,000			$ 100,000			$ 57,300		$ 57,300		$ 57,300
Percentage of stock price trigger																									85%
Administrative fees expense																									$ 750
Variable interest, percentage rate																									125%
Number of restricted shares \| shares																									95,500
Debt instrument, effective conversion price \| $ / shares																									$ 1.188
Share price \| $ / shares																									$ 1.390
Beneficial conversion feature																									$ 66,068
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] \| Maximum [Member]
Class of warrant or right, number of shares \| shares																									100,000
Variable interest, percentage rate																									16%
First Fire Note and First Fire Warrant [Member]
Debt instrumment converted amount																									$ 515,700
Streeterville Securities Purchase Agreement [Member]
Debt instrument, face value					$ 6,210,000															$ 277,777.77												235,414					$ 3,500,000
Maturity date					Apr. 08, 2025
Debt instrument, unamortized discount																																3,505,848
Debt amortized discount																																2,380,117
Debt instrument, interest rate, effective percentage					10.90%
Percentage of stock price trigger					85%
Original issue discount					$ 660,000
Transaction costs					$ 50,000
Repayments of debt				$ 5,500,000
Redeemable amount	$ 950,000
Common stock percentage					19.99%
Fair value of the derivative liability					$ 5,010,966																											4,685,198
Change in fair value of derivative liability																																$ 322,383
Terragenx Inc [Member]
Ownership percentage																															91%
Terragenx Inc [Member] \| Promissory Notes Payment [Member]
Convertible notes payable																													$ 1,875,000
Notes payable																													948,874
Terragenx Inc [Member] \| Promissory Notes Payment and Extension [Member]
Convertible notes payable																													1,875,000
Notes payable																													937,500
Convertible notes payable																													$ 192,188
Maturity date																													Nov. 29, 2022
Jefferson Street Capital [Member]
Convertible notes payable																													$ 1,875,000
Notes payable																													$ 186,719
Maturity date																													Nov. 29, 2022
Debt conversion, converted instrument, shares issued \| shares																							236,511
Warrant [Member]
Debt instrument, face value																														$ 5,257,466
Warrants and rights outstanding, term																																3 years
Estimated value of the warrants																																	1,137,959
Warrant [Member] \| Mast Hill Securities Purchase Agreement [Member]
Debt instrument, face value																								$ 77,856			86,327
Warrant [Member] \| First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt instrument, face value																									93,811
Common Stock [Member]
Debt conversion, converted instrument, shares issued \| shares																																24,608,975
Other fees																																	140,000
Common Stock [Member] \| Mast Hill Securities Purchase Agreement [Member]
Debt instrument, face value																								74,793			82,963
Common Stock [Member] \| First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt instrument, face value																									90,132
Convertible Debt [Member]
Debt instrument, face value																														$ 11,409,200	$ 1,579,176
Convertible Debt [Member] \| Mast Hill Securities Purchase Agreement [Member]
Debt instrument, face value																								$ 292,351			$ 403,710
Convertible Debt [Member] \| First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt instrument, face value																									$ 389,057
Warrant [Member]
Debt instrument, face value																															$ 295,824
Convertible Notes [Member]
Debt instrument, unamortized discount																																		$ 0
Debt amortized discount																																		$ 760,824
Measurement Input, Expected Term [Member]
Warrants and rights outstanding, term																								5 years	5 years		5 years			4 years	3 years
Measurement Input, Expected Term [Member] \| Streeterville Securities Purchase Agreement [Member]
Derivative liability, measurement input, term					1 year																											7 months 6 days
Measurement Input, Price Volatility [Member]
Warrants measurement input percentage																								251	251		252			275	300
Measurement Input, Price Volatility [Member] \| Streeterville Securities Purchase Agreement [Member]
Derivative liability measurement input percentage					186																											200
Measurement Input, Expected Dividend Rate [Member]
Warrants measurement input percentage																								0	0		0			0	0
Measurement Input, Expected Dividend Rate [Member] \| Streeterville Securities Purchase Agreement [Member]
Derivative liability measurement input percentage					0																											0
Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input percentage																								3.96	3.73		4.09			1.23	0.85
Measurement Input, Risk Free Interest Rate [Member] \| Streeterville Securities Purchase Agreement [Member]
Derivative liability measurement input percentage					5.05																											4.38
Two Convertible Notes [Member]
Debt instrument, face value																														$ 16,666,666
Interest Rate, Stated Percentage																														5%
Maturity date																														Jun. 14, 2023
Debt instrument conversion price \| $ / shares																														$ 20
Convertible notes payable, note holders issued warrants to purchase total, shares \| shares																														583,334
Exercise price of warrants or rights \| $ / shares																														$ 20
Warrant maturity date																														Dec. 14, 2025
Estimated value warrants																														$ 7,680,156
Discount on convertable note and additional paid in capital																														5,257,466
Debt instrument, unamortized discount																														1,666,666
Loan fees																														1,140,000
Debt amortized discount																														8,064,132
Convertible notes payable																																							$ 16,660,000
Two Convertible Notes [Member] \| Terragenx Inc [Member]
Debt instrument, face value																															$ 1,875,000
Interest Rate, Stated Percentage																															1%
Maturity date																															May 17, 2022
Debt instrument conversion price \| $ / shares																															$ 33.50
Convertible notes payable, note holders issued warrants to purchase total, shares \| shares																															22,388
Exercise price of warrants or rights \| $ / shares																															$ 33.50
Warrant maturity date																															Nov. 17, 2024
Estimated value warrants																															$ 351,240
Discount on convertable note and additional paid in capital																															295,824
Debt instrument, unamortized discount																															375,000
Loan fees																															90,000
Debt amortized discount																															760,824
Convertible Debt One [Member]
Debt instrument, face value																														8,333,333
Convertible Debt One [Member] \| Terragenx Inc [Member]
Debt instrument, face value																															937,500
Convertible Debt Two [Member]
Debt instrument, face value																														$ 8,333,333
Convertible Debt Two [Member] \| Terragenx Inc [Member]
Debt instrument, face value																															$ 937,500
Convertible Notes [Member] \| Mast Hill Securities Purchase Agreement [Member]
Debt instrument, unamortized discount																																	269,123
Debt amortized discount																								$ 335,031									$ 65,908

Debentures, related parties (De

Debentures, related parties (Details Narrative)						12 Months Ended
Debentures, related parties (Details Narrative)	Nov. 02, 2021	Jul. 21, 2020 USD ($)	Jan. 31, 2018 USD ($) $ / shares shares	Dec. 02, 2017	Sep. 30, 2013 USD ($)	Aug. 31, 2024 USD ($)	Aug. 31, 2023 USD ($)	Sep. 30, 2013 CAD ($)
Short-Term Debt [Line Items]
Debentures, outstanding						$ 913,598	$ 916,824
Repayment of related party debt		$ 267,768				$ (396,418)	$ 7,206
Five Debentures [Member]
Short-Term Debt [Line Items]
Debentures, outstanding					$ 6,225,163			$ 6,402,512
Debt interest rate					8%			8%
Debt due date	Dec. 01, 2023			Sep. 30, 2019	Sep. 30, 2016
Debentures [Member]
Short-Term Debt [Line Items]
Debentures, outstanding			$ 3,894,809
Percentage of debt converted			75%
Accrued interest			$ 414,965
Debt converted, shares issued \| shares			1,047,588
Debt conversion price \| $ / shares			$ 4.11
Debt conversion description			the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

Schedule of Lease Related Asset

Schedule of Lease Related Assets and Liabilities (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Leases
Operating lease assets	$ 1,691,309	$ 1,983,898
Total lease assets	1,691,309	1,983,898
Current liabilities- Operating lease liability	403,291	415,392
Noncurrent liabilities - Operating lease liability	1,440,367	1,693,577
Total lease liability	$ 1,843,658	$ 2,108,969

Schedule of Lease Obligations (

Schedule of Lease Obligations (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Leases
2025	$ 547,571
2026	547,393
2027	510,676
2028	293,723
2029	173,588
Thereafter	167,269
Total payments	2,240,220
Amount representing interest	(396,562)
Lease obligation, net	1,843,658	$ 2,108,969
Less lease obligation, current portion	(403,291)	(415,392)
Lease obligation, long-term portion	$ 1,440,367	$ 1,693,577

Schedule of Finance Leases (Det

Schedule of Finance Leases (Details)	Aug. 31, 2024 USD ($)
Leases
Cost	$ 209,457
Accumulated amortization	(209,457)
Net book value
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Leases
2025	$ 4,420
Total payments	4,420
Amount representing interest	(66)
Lease obligation, net	4,354
Less lease obligation, current portion	(4,354)	$ (11,744)
Lease obligation, long-term portion
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Liabilities

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	12 Months Ended
Leases (Details Narrative) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Leases
Purchase obligation	$ 157,973
Lease expense	616,799	$ 797,515
Cash paid under operating leases	$ 589,138	$ 772,655
Weighted average remaning lease term	3 years 9 months
Weighted average discount rate	8.70%
Lease payments implicit borrowing rate	5%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
Schedule of Stock Option Activity (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023	Aug. 31, 2022
Equity [Abstract]
Options outstanding, beginning balance	371,423	216,423
Weighted average exercise price, outstanding, beginning balance	$ 11.44	$ 21.50
Weighted average remaining contractual life, outstanding	3 years 5 months 1 day		2 years 6 months 10 days
Aggregate intrinsic value, outstanding, beginning balance	$ 16,000	$ 140,577
Options outstanding, granted	200,000	200,000
Weighted average exercise price, granted	$ 0.78	$ 1.32
Weighted average remaining contractual life, outstanding, granted		5 years 9 months
Options outstanding, expired	(33,000)	(45,000)
Options Outstanding, Exercised
Weighted average remaining contractual life, outstanding	3 years 11 months 23 days
Options outstanding, ending balance	538,423	371,423	216,423
Weighted average exercise price, outstanding, ending balance	$ 7.17	$ 11.44	$ 21.50
Aggregate intrinsic value, outstanding, ending balance		$ 16,000	$ 140,577
Options outstanding, exercisable	538,423
Weighted average exercise price, exercisable	$ 7.17
Weighted average remaining contractual life, exercisable	3 years 5 months 1 day
Aggregate intrinsic value, exercisable

Schedule of Options Outstanding

Schedule of Options Outstanding and Exercisable (Details) - $ / shares	Aug. 31, 2024	Aug. 31, 2023	Aug. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options, Outstanding	538,423	371,423	216,423
Number of Options, Exercisable	538,423
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options, Outstanding	22,715
Exercise price, outstanding	$ 13.3
Number of Options, Exercisable	22,715
Exercise price, Exercisable	$ 13.3
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options, Outstanding	21,700
Exercise price, outstanding	$ 16
Number of Options, Exercisable	21,700
Exercise price, Exercisable	$ 16
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options, Outstanding	4,800
Exercise price, outstanding	$ 18.7
Number of Options, Exercisable	4,800
Exercise price, Exercisable	$ 18.7
Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options, Outstanding	77,500
Exercise price, outstanding	$ 30
Number of Options, Exercisable	77,500
Exercise price, Exercisable	$ 30
Exercise Price Range Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options, Outstanding	7,260
Exercise price, outstanding	$ 38
Number of Options, Exercisable	7,260
Exercise price, Exercisable	$ 38
Exercise Price Range Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options, Outstanding	500
Exercise price, outstanding	$ 50
Number of Options, Exercisable	500
Exercise price, Exercisable	$ 50
Exercise Price Range Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options, Outstanding	3,948
Exercise price, outstanding	$ 19
Number of Options, Exercisable	3,948
Exercise price, Exercisable	$ 19
Exercise Price Range Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options, Outstanding	200,000
Exercise price, outstanding	$ 1.32
Number of Options, Exercisable	200,000
Exercise price, Exercisable	$ 1.32
Exercise Price Range Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options, Outstanding	200,000
Exercise price, outstanding	$ 0.78
Number of Options, Exercisable	200,000
Exercise price, Exercisable	$ 0.78

Schedule of Fair Value of Optio

Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details)	12 Months Ended
	Aug. 31, 2024	Aug. 31, 2023
Equity [Abstract]
Risk-free interest rate	4.01%	3.74%
Expected life of the options	6 years	6 years
Expected volatility	246%	254%
Expected dividend yield		0%

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details) - USD ($)	12 Months Ended
Schedule of Warrant Activity (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Equity [Abstract]
Warrants outstanding, beginning balance	806,254	844,526
Weighted average exercise price, outstanding, beginning balance	$ 12.05	$ 24.18
Weighted average remaining contractual life, outstanding, beginning balance	3 years 8 months 15 days	3 years 6 months
Aggregate intrinsic value, outstanding, beginning balance	$ 106,960
Warrants outstanding, granted		1,077,661
Weighted average exercise price, granted		$ 1.39
Weighted average remaining contractual life, granted		3 years 6 months 3 days
Warrants outstanding, forfeited
Warrants outstanding, exercised	(518,061)	(1,115,933)
Warrants outstanding, ending balance	288,193	806,254
Weighted average exercise price, outstanding, ending balance	$ 30.46	$ 12.05
Weighted average remaining contractual life, outstanding, ending balance	2 years 8 months 15 days
Aggregate intrinsic value, outstanding, ending balance		$ 106,960
Warrants outstanding, exercisable	288,193

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - $ / shares	Aug. 31, 2024	Aug. 31, 2023	Aug. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	288,193	806,254	844,526
Exercise Price, Outstanding and Exercisable	$ 30.46	$ 12.05	$ 24.18
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable		261,193
Exercise Price, Outstanding and Exercisable		$ 33.50
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable		27,000
Exercise Price, Outstanding and Exercisable		$ 1
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable
Exercise Price, Outstanding and Exercisable
Exercise Price Range [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable		288,193

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

12 Months Ended

Nov. 07, 2023

Oct. 23, 2023

Sep. 18, 2023

Sep. 12, 2023

Aug. 24, 2023

Aug. 21, 2023

Aug. 18, 2023

Aug. 17, 2023

Aug. 01, 2023

Jul. 03, 2023

Jun. 28, 2023

Jun. 20, 2023

Jun. 01, 2023

May 11, 2023

May 10, 2023

Mar. 21, 2023

Mar. 17, 2023

Mar. 08, 2023

Mar. 06, 2023

Feb. 24, 2023

Feb. 23, 2023

Jan. 12, 2023

Jan. 05, 2023

Dec. 29, 2022

Nov. 14, 2022

Jun. 24, 2021

Feb. 09, 2021

Aug. 31, 2024

Aug. 31, 2023

Aug. 31, 2022

Jul. 26, 2023

Dec. 14, 2021

Nov. 17, 2021

Jan. 16, 2018

Sep. 08, 2015

Accumulated Other Comprehensive Income (Loss) [Line Items]

Convertible preferred stock, shares authorized

1,000,000

Convertible preferred stock, par value

$ 0.001

Convertible preferred stock, shares issued

Convertible preferred stock, shares outstanding

Common stock, shares authorized

499,000,000

Common stock, par value

$ 0.001

Reverse stock split

1-for-10 reverse stock split

Common stock, shares issued

19,054,523

15,759,325

Common stock, shares outstanding

19,054,523

15,759,325

Number of shares issued

400,000

Proceeds of warrants

$ 240,400

$ 532,600

Number of shares issued for reverse stock split

27,973

Number of shares issued

522,777

Value of shares issued

$ 580,778

1,610,883

9,968,140

Proceeds from the sale of common stock, net of offering costs

$ 1,795,000

Estimated shares granted for warrants

1,077,661

Expected Voltality

246%

254%

Dividend yield

Risk free interet rate

4.01%

3.74%

Expected life

6 years

Number of shares issued

$ 1,795,000

Common stock to be issued

$ 25,500

$ 1,217,293

Weighted average fair value options

$ 1.32

$ 13.72

Weighted-average exercise price

$ 1.32

14.24

Stock option expense

147,656

$ 385,335

Unamortized stock option expense

2015 Incentive Compensation Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares available for future grant

49,875

2018 Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock shares available for award

100,000

Number of shares available for future grant

86,490

2021 Equity Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock shares available for award

450,000

Number of shares available for future grant

75,465

Term of award description

the maximum aggregate
number of shares that may be issued under the 2021 Plan may be cumulatively increased on January 1, 2022 and on each subsequent January
1 through and including January 1, 2023, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock
issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company
chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan effective January 1, 2022 and January 1, 2023.
As of August 31, 2024, the 2021 Plan had 75,465 shares available for award; however, the Company does not intend to issue any additional
grants under the 2021 Plan

2023 Equity Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock shares available for award

2,300,000

Taddeo Hovius Physiotherapy Professional Corp [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issued for acquisition, shares

1,700

Common stock to be issued

$ 25,500

Debt Holder One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

3,916,596

Value of shares issued

$ 3,825,307

Debt issuance date

Feb. 28, 2023

Debt Holder Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

4,503,644

Value of shares issued

$ 4,503,640

Debt issuance date

Feb. 28, 2023

Debt Holder Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

890,711

Value of shares issued

$ 757,103

Debt issuance date

Feb. 28, 2023

Warrant Holders One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise warrants term

3 years

Proceeds of warrants

$ 65,000

Warrants to purchase common stock

65,000

Warrant Holders Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise warrants term

5 years

Proceeds of warrants

$ 33,000

Warrants to purchase common stock

33,000

Warrant Holders Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise warrants term

3 years

Proceeds of warrants

$ 33,000

Warrants to purchase common stock

33,000

Debt Holder Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

53,812

53,783

107,595

Value of shares issued

$ 100,278

Warrant Holder Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

30,000

Exercise warrants term

5 years

3 years

Proceeds of warrants

$ 160,000

Warrants to purchase common stock

160,000

Number of shares issued

$ 30,000

Warrant Holder Five [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise warrants term

5 years

Proceeds of warrants

$ 100,000

Warrants to purchase common stock

100,000

Warrant Holder Six [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise warrants term

5 years

Proceeds of warrants

$ 30,000

Warrants to purchase common stock

30,000

Warrant Holder Seven [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise warrants term

3 years

Proceeds of warrants

$ 30,000

Warrants to purchase common stock

30,000

Warrantholder One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

20,800

Exercise warrants term

3 years

Number of shares issued

$ 20,800

Warrantholder Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

20,800

Exercise warrants term

5 years

Number of shares issued

$ 20,800

Warrantholder Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

10,000

Exercise warrants term

3 years

Number of shares issued

$ 10,000

Jefferson [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

236,511

Liquidated damages

$ 201,034

Liquidated damages charge

186,719

Liquidated damages interest

$ 14,315

Board of Directors Chairman [Member] | 2023 Equity Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock shares available for award

2,500,000

Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average fair value options

18.01

Weighted-average exercise price

$ 19

Maximum [Member] | 2015 Incentive Compensation Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock shares available for award

50,000

Consulting Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

75,000

Shares issuance date

Sep. 05, 2023

Mast Hill Warrant Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issuance date

Sep. 18, 2023

Number of warrant exercised

53,567

Debt instrument aggregate principal amount

$ 573,000

Consulting Agreement One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

75,000

Shares issuance date

Sep. 18, 2023

FirstFire Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

519,845

Debt instrument aggregate principal amount

$ 573,000

Interest payable

4,521

Total amount

$ 577,521

Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

100,000

74,167

95,500

Shares issuance date

Mar. 22, 2023

Sep. 21, 2023

Consulting Agreement Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

75,000

Shares issuance date

Oct. 03, 2023

Share Exchange Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

73,767

Shares issuance date

Oct. 09, 2023

Share issued price per share

$ 33.50

First Fire Warrant Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issuance date

Oct. 12, 2023

Number of warrant exercised

53,532

Debt instrument aggregate principal amount

$ 573,000

Consulting Agreement Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

75,000

Shares issuance date

Oct. 18, 2023

Mast Hill Securities Warrant Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issuance date

Oct. 23, 2023

Number of warrant exercised

138,703

Debt instrument aggregate principal amount

$ 445,000

Consulting Agreement Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

75,000

Shares issuance date

Nov. 08, 2023

Executive Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

30,675

Shares issuance date

Nov. 21, 2023

Executive Agreement One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

18,405

Shares issuance date

Nov. 21, 2023

Mast Hill Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

138,703

53,567

74,167

95,500

Shares issuance date

Dec. 21, 2023

Debt instrument aggregate principal amount

$ 580,778

$ 445,000

$ 573,000

$ 445,000

Interest payable

$ 9,071

6,028

Number of shares issued

457,128

Value of shares issued

$ 454,071

Warrants exercise price

$ 2.50

Cash fee

$ 1,750

Fair value of warrant granted

$ 77,856

Mast Hill Securities Purchase Agreement One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Debt instrument aggregate principal amount

271,226

Interest payable

104,712

Number of shares issued

826,203

Value of shares issued

$ 375,938

Shares issuance date description

between March 14, 2024 and April
4, 2024

First Fire Securities Purchase Agreement One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issuance date

Apr. 04, 2024

Debt instrument aggregate principal amount

$ 195,016

Interest payable

8,333

Number of shares issued

480,000

Value of shares issued

$ 203,350

Share Exchange Agreement One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

3,623

Shares issuance date

Oct. 26, 2022

Hudson Bay [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

291,667

Shares issuance date

Nov. 15, 2022

CVI Exchange Offer and Amendment [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

175,732

Shares issuance date

Nov. 15, 2022

CVI Exchange Offer and Amendment One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

115,935

Share Exchange Agreement Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

320,204

Shares issuance date

Jan. 25, 2023

Share Exchange Agreement Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

95,500

Shares issuance date

Feb. 24, 2023

Separation and Release Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

33,500

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

80,200

Exercise warrants term

3 years

Proceeds of warrants

$ 80,200

Debt instrument aggregate principal amount

$ 5,257,466

Share issued price per share

$ 2.956

Proceeds from issuance of common stock

$ 2,000,000

Estimated shares granted for warrants

800,000

Fair value of warrant granted

$ 1,137,959

Dividend yield

Warrant [Member] | Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Expected Voltality

149.06%

Expected life

3 years

Warrant [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Risk free interet rate

2.55%

Warrant [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Expected Voltality

206.90%

Expected life

5 years

Warrant [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Risk free interet rate

2.89%

Warrant [Member] | Mast Hill Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Debt instrument aggregate principal amount

77,856

$ 86,327

Warrant One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

160,200

400,000

Exercise warrants term

5 years

3 years

Proceeds of warrants

$ 160,200

Warrants to purchase common stock

400,000

Warrants exercise price

$ 5

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

400,000

Number of shares issued

2,283,176

10,177,834

Value of shares issued

$ 2,283

$ 10,178

Share issued price per share

$ 5

Unit offering description

The Company sold an aggregate of 400,000 units for aggregate gross proceeds of $2,000,000, consisting of 400,000 common
stock, 400,000 warrants with a three-year term to purchase 400,000 shares of common stock at an exercise price of $5 per share, and
400,000 warrants with a five-year term to purchase 400,000 shares of common stock at an exercise price of $5 per share

Cash fee

$ 140,000

Percentage of issuance of offering

Proceeds from the sale of common stock, net of offering costs

$ 1,795,000

Number of shares issued

$ 400

Common Stock [Member] | Mast Hill Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Debt instrument aggregate principal amount

$ 74,793

$ 82,963

Warrant Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

400,000

Exercise warrants term

5 years

Warrants to purchase common stock

400,000

Warrants exercise price

$ 5

Schedule of Effective and Statu

Schedule of Effective and Statutory Income Tax Rates (Details) - USD ($)	12 Months Ended
	Aug. 31, 2024	Aug. 31, 2023
Pretax income (loss)	$ (16,166,744)	$ (13,214,552)
Expected income tax expense (benefit)	(4,341,783)	(3,550,349)
Stock based compensation	233,800	233,800
Change in valuation allowance	4,365,942	3,316,549
Total
Total percentage	0%	0%
CANADA
Combined statutory tax rate	26.50%	26.50%
Pretax income (loss)	$ (4,647,448)	$ (3,515,747)
Expected income tax expense (benefit)	$ (1,231,573)	$ (931,672)
Expected income tax expense (benefit), percentage	(26.50%)	(26.50%)
Stock based compensation
Stock based compensation, percentage	0%	0%
Change in valuation allowance	$ 1,231,573	$ 931,672
Change in valuation allowance, percentage	26.50%	26.50%
Total
Total percentage	0%	0%
UNITED STATES
Combined statutory tax rate	27%	27%
Pretax income (loss)	$ (11,519,296)	$ (9,698,805)
Expected income tax expense (benefit)	$ (3,110,210)	$ (2,618,677)
Expected income tax expense (benefit), percentage	(27.00%)	(27.00%)
Stock based compensation	$ (24,159)	$ 233,800
Stock based compensation, percentage	0.80%	9%
Change in valuation allowance	$ 3,134,369	$ 2,384,877
Change in valuation allowance, percentage	27.80%	18%
Total
Total percentage	0%	0%

Schedule of the Deferred Tax As

Schedule of the Deferred Tax Assets (Details) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 20,205,889	$ 15,839,947
Total deferred tax asset	20,205,889	15,839,947
Less: valuation allowance	(20,205,889)	(15,839,947)
Total deferred tax asset
Intangible assets	(1,395,571)	(1,400,499)
Total deferred tax liability	(1,395,571)	(1,400,499)
Net deferred tax liability	$ (1,395,571)	$ (1,400,499)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Aug. 31, 2024	Aug. 31, 2023
Deferred income tax
Deferred tax valuation allowances	20,205,889	15,839,947
Operating loss carry forward	$ 20,205,889	15,839,947
UNITED STATES
Operating loss carry forward		$ 12,276,498

Summary of Purchase Price Alloc

Summary of Purchase Price Allocation at Fair Value (Details) - USD ($)		12 Months Ended
	Mar. 17, 2022	Aug. 31, 2024	Aug. 31, 2023	Aug. 31, 2022
Business Acquisition [Line Items]
Cash and cash equivalents		$ 29,291
Inventory		42,273
Prepaid expenses and other current assets		398
Property and equipment		66,759
Intangible assets		1,179,361
Accounts payable and accrued expenses		(189,080)
CEBA loan		(47,766)
Minority interest		(97,311)
Purchase price		983,925
Goodwill		6,554,473	$ 7,582,483	$ 7,825,844
Canada Corp [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		7,629
Property and equipment		8,813
Intangible assets		31,101
Minority interest		(25,401)
Purchase price		25,500
Accounts receivable		2,754
Goodwill		602
Poling Taddeo Hovius Physiotherapy Professional Corp [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		18,383
Prepaid expenses and other current assets		11,292
Property and equipment		9,475
Purchase price		235,125
Accounts receivable		44,289
Intangible asset		151,686
Clinical Consultants International LLC [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		2,186
Purchase price	$ 1,704,000	1,704,000
Intangible asset		$ 1,701,814

Summary of Purchase Price (Deta

Summary of Purchase Price (Details) - USD ($)		12 Months Ended
Summary of Purchase Price (Details) - USD ($)	Mar. 17, 2022	Aug. 31, 2024
Business Acquisition [Line Items]
Cash
Common stock		983,925
Purchase price, total		983,925
Canada Corp [Member]
Business Acquisition [Line Items]
Cash
Common stock		25,500
Purchase price, total		25,500
Poling Taddeo Hovius Physiotherapy Professional Corp [Member]
Business Acquisition [Line Items]
Cash
Common stock		235,125
Purchase price, total		235,125
Clinical Consultants International LLC [Member]
Business Acquisition [Line Items]
Cash
Common stock		1,704,000
Purchase price, total	$ 1,704,000	$ 1,704,000

Acquisitions (Details Narrative

Acquisitions (Details Narrative)							12 Months Ended
Acquisitions (Details Narrative)	Mar. 17, 2022 USD ($)	Mar. 17, 2022 USD ($) shares	Mar. 02, 2022 USD ($) $ / shares shares	Nov. 17, 2021 USD ($) $ / shares shares	Nov. 17, 2021 CAD ($) shares	Oct. 08, 2021 CAD ($) shares	Aug. 31, 2024 USD ($) shares	Aug. 31, 2023 USD ($) shares	Mar. 17, 2021 USD ($)
Business Acquisition [Line Items]
Number of shares, issued \| shares								400,000
Stock issued during period, value, new issues								$ 1,795,000
Business combination consideration transferred							$ 983,925
Canada Corp [Member]
Business Acquisition [Line Items]
Allotment of restricted shares \| shares			1,700
Business combination consideration transferred							25,500
Purchase price			$ 68,000
Purchase price per share \| $ / shares			$ 40
Poling Taddeo Hovius Physiotherapy Professional Corp [Member]
Business Acquisition [Line Items]
Allotment of restricted shares \| shares			15,675
Business combination consideration transferred							235,125
Purchase price			$ 627,000
Purchase price per share \| $ / shares			$ 40
Clinical Consultants International LLC [Member]
Business Acquisition [Line Items]
Allotment of restricted shares \| shares		80,000
Business combination consideration transferred	$ 1,704,000						1,704,000
Canada Corp [Member]
Business Acquisition [Line Items]
Ownership percentage			50.10%
Clinical Consultants International LLC [Member]
Business Acquisition [Line Items]
Ownership percentage	100%	100%
Terragenx Inc [Member]
Business Acquisition [Line Items]
Ownership percentage				91%	91%
Clinical Consultants International LLC [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Business combination, recognized intangible assets	$ 1,701,814	$ 1,701,814						$ 317,314
Joint Venture Agreement [Member]
Business Acquisition [Line Items]
Proceeds from joint venture						$ 1,500,000
Number of shares, issued \| shares						185,000
Mullins Asset Purchase Agreement [Member]
Business Acquisition [Line Items]
Purchase of assets				$ 1,990,250	$ 2,500,000
Shares issued price per share \| $ / shares				$ 33.50
Share price \| $ / shares				$ 15.90
Asset acquisition consideration payments				$ 755,701
Asset acquisition consideration transferred				$ 188,925
Royalty paid description				the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales reported through the Company or any of its wholly owned subsidiaries for a period equal to the commercial validity of the intellectual property.	the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales reported through the Company or any of its wholly owned subsidiaries for a period equal to the commercial validity of the intellectual property.
Mullins Asset Purchase Agreement [Member] \| Mr Mullins [Member]
Business Acquisition [Line Items]
Stock issued during period, value, new issues				$ 1,592,200	$ 2,000,000
Shares issued, restricted stock, value				$ 398,050	$ 500,000
Allotment of restricted shares \| shares				11,883	11,883
Mullins Asset Purchase Agreement [Member] \| Terragenx [Member] \| Mr Mullins [Member]
Business Acquisition [Line Items]
Number of shares issued, value				CAD$2,000,000 (approximately $1,592,200) is to be issued or allotted to Mr. Mullins only after patent-pending status, in the U.S. or internationally, is designated for all Mullins IP Assets (the “Mullins IP Assets CAD$2m Shares”), as either restricted shares of Company common stock or NHL Exchangeable Shares, as determined by Mr. Mullins. Once issued or allotted, the Mullins IP Assets CAD $2m Shares will be held in escrow pending registration	CAD$2,000,000 (approximately $1,592,200) is to be issued or allotted to Mr. Mullins only after patent-pending status, in the U.S. or internationally, is designated for all Mullins IP Assets (the “Mullins IP Assets CAD$2m Shares”), as either restricted shares of Company common stock or NHL Exchangeable Shares, as determined by Mr. Mullins. Once issued or allotted, the Mullins IP Assets CAD $2m Shares will be held in escrow pending registration
Share Exchange Agreement [Member]
Business Acquisition [Line Items]
Allotment of restricted shares \| shares							73,767
Shares issued price per share \| $ / shares				$ 33.50
Business combination consideration transferred				$ 398,050	$ 500,000
Share Exchange Agreement [Member] \| Terragenx Inc [Member]
Business Acquisition [Line Items]
Ownership percentage				91%	91%
Share Exchange Agreement [Member] \| Novo Healthnet Limited [Member]
Business Acquisition [Line Items]
Number of shares, issued \| shares				910	910
Ownership percentage				91%	91%
Share exchange, description				At the closing of the Exchange, (i) the Terra Shareholders transferred to NHL a total of 910 shares of Terra common stock, representing 91% of Terra’s outstanding shares, and (ii) a total of 100 NHL Exchangeable Shares were issued to the Terra Shareholders, which NHL Exchangeable Shares are exchangeable into a total of 11,883 restricted shares of the Company’s common stock. As a result of the Exchange, NHL has 91% ownership of Terra and full control of the Terra business.	At the closing of the Exchange, (i) the Terra Shareholders transferred to NHL a total of 910 shares of Terra common stock, representing 91% of Terra’s outstanding shares, and (ii) a total of 100 NHL Exchangeable Shares were issued to the Terra Shareholders, which NHL Exchangeable Shares are exchangeable into a total of 11,883 restricted shares of the Company’s common stock. As a result of the Exchange, NHL has 91% ownership of Terra and full control of the Terra business.
Numnber of shares issued \| shares				100	100
Shares exchanged, shares \| shares				11,883	11,883
Share Exchange Agreement [Member] \| Terragenx [Member]
Business Acquisition [Line Items]
Share price \| $ / shares				$ 15.90
Business combination consideration transferred				$ 983,925
Share Exchange Agreement [Member] \| Terragenx [Member] \| Terry Mullins [Member]
Business Acquisition [Line Items]
Number of shares, issued \| shares				50,000	50,000
Cloud DX Amendment [Member] \| Clinical Consultants International LLC [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Business combination, recognized intangible assets									$ 1,701,814

Schedule of Segment Reporting I

Schedule of Segment Reporting Information (Details) - USD ($)	12 Months Ended
	Aug. 31, 2024	Aug. 31, 2023	Aug. 31, 2022
Segment Reporting Information [Line Items]
Sales	$ 13,294,357	$ 12,572,019
Gross profit	5,742,504	4,952,715
Income (loss) from operations	(10,076,298)	(8,553,162)
Depreciation and amortization	2,261,519	2,302,754
Capital expenditures	5,034	49,224
Interest expenses	652,398	360,571
Net loss	(16,128,570)	(13,269,444)
Total assets	32,141,276	35,563,047
Accounts receivable	1,916,819	1,467,028
Intangible assets	13,369,868	16,218,539
Goodwill	6,554,473	7,582,483	$ 7,825,844
Healthcare Services [Member]
Segment Reporting Information [Line Items]
Sales	8,297,530	8,226,674
Gross profit	3,103,780	2,998,315
Income (loss) from operations	(397,316)	(413,670)
Depreciation and amortization	120,327	132,539
Capital expenditures
Interest expenses	82,943	92,327
Net loss	(996,293)	(496,970)
Total assets	4,759,470	5,158,851
Accounts receivable	724,624	697,440
Intangible assets	14,553	120,163
Goodwill	259,776	520,821
Product Sales [Member]
Segment Reporting Information [Line Items]
Sales	4,918,577	4,335,645
Gross profit	2,560,474	1,944,701
Income (loss) from operations	(3,032,650)	(2,958,225)
Depreciation and amortization	1,023,424	1,052,406
Capital expenditures	5,034	49,224
Interest expenses	7,628	55,441
Net loss	(4,013,231)	(3,193,859)
Total assets	16,366,290	17,993,652
Accounts receivable	1,175,499	765,388
Intangible assets	2,850,617	3,818,313
Goodwill	6,294,697	7,061,662
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Sales	78,250	9,700
Gross profit	78,250	9,699
Income (loss) from operations	(6,646,332)	(5,181,267)
Depreciation and amortization	1,117,768	1,117,809
Capital expenditures
Interest expenses	561,827	212,803
Net loss	(11,119,046)	(9,578,615)
Total assets	11,015,516	12,410,544
Accounts receivable	16,696	4,200
Intangible assets	10,504,698	12,280,063
Goodwill

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)						12 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Nov. 22, 2024	Oct. 21, 2024	Oct. 16, 2024	Oct. 08, 2024	Nov. 07, 2023	Aug. 31, 2024	Aug. 31, 2023	Sep. 23, 2024
Subsequent Event [Line Items]
Common stock shares registered for issuance						499,000,000	499,000,000
Repayments of notes payable						$ 183,725	$ 37,130
Reverse stock split					1-for-10 reverse stock split
Subsequent Event [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Reverse stock split	1-for-10
Subsequent Event [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Reverse stock split	1-for-30
Subsequent Event [Member] \| Streeterville Capital LLC [Member]
Subsequent Event [Line Items]
Repayments of notes payable				$ 950,000
Redemption fee amount				$ 142,500
Percentage of debt redemption amount by way of fee				15%
Total debt redemption amount				$ 950,000
Stock redemption, value		$ 142,500	$ 142,500
Number of shares for redemption		675,724
Outstanding Balance of notes payable		$ 6,579,657.54
Subsequent Event [Member] \| Equity Incentive Plan 2023 [Member]
Subsequent Event [Line Items]
Common stock shares registered for issuance								2,500,000